



Supporting Information

Chiral Phosphoric Acid Catalyzed Asymmetric Hydrolysis of Biaryl Oxazepines for the Synthesis of Axially Chiral Biaryl Amino Phenol Derivatives

L. Wei, J. Li, Y. Zhao, Q. Zhou, Z. Wei, Y. Chen, X. Zhang, X. Yang**

Supporting Information

Contents


General methods.....	S2
General procedures	S3
Synthetic applications	S6
Synthesis of chiral phosphoric acid catalyst	S7
Determination of the rotational barriers	S9
Mechanism studies.....	S10
Characterization data of the catalytic reaction products	S22
X-ray structure of 1c and 2c.....	S56
^1H, ^{13}C, and ^{19}F NMR spectra and HPLC charts.....	S57
References.....	S175

General methods

All reactions and manipulations involving air-sensitive compounds were carried out using standard Schlenk techniques. Anhydrous toluene and cyclohexane were distilled from CaH₂ under an atmosphere of nitrogen. All reactions were monitored by TLC. TLC analysis was performed by illumination with a UV lamp (254 nm). All flash chromatography was packed with silica-gel as the stationary phase. ¹H NMR spectra were recorded on a Bruker AVIII-500 (500 MHz) instrument, and chemical shifts were reported in ppm downfield from internal TMS with the solvent resonance as the internal standard (CDCl₃, δ = 7.26 ppm; DMSO, δ = 2.49 ppm). ¹³C NMR spectra were recorded on a Bruker (126 MHz) instrument, and chemical shifts were reported in ppm downfield from TMS with the solvent resonance as the internal standard (CDCl₃, δ = 77.00 ppm; DMSO, δ = 39.50 ppm). ¹⁹F NMR spectra were recorded on a Bruker (471 MHz) instrument. Optical rotations were measured on a WZZ-2B polarimeter. High resolution mass spectra (HRMS) (EI+) were recorded on an a Finnigan MAT 95 XP mass spectrometer. The racemic biaryl amides were synthesized according to the literature procedures.^[1-3]


General procedures

General procedure for the Mitsunobu reaction.



To a dried 4 mL tube with a stir bar was added the PPh_3 (0.9 mmol), anhydrous toluene (3.0 mL). And the reaction mixture was stirred at room temperature to form a homogeneous phase. Then DEAD (0.9 mmol) was add and stirred for 2-3 minutes and $(rac)\text{-}2$ (0.3 mmol) was added into the homogeneous mixture. The test tube was sealed and stirred at $110\text{ }^\circ\text{C}$ for 12 h. Then the reaction mixture was directly purified by column chromatography ($\text{PE/DCM/Et}_3\text{N} = 80:1:1$) to afford the desired products **1**.


General procedure for the CPA-catalyzed asymmetric reaction




To a dried 4 mL tube with a stir bar was added the $(R)\text{-C2}$ (10 mol%), anhydrous cyclohexane (2 ml) and H_2O (5 μl). Then the reaction mixture was stirred at RT for 2 minutes and **1** (0.1 mmol) was added to the reaction mixture. The test tube was sealed and stirred at room temperature for 1-7 days until the starting material disappeared as indicated by TLC. Then the reaction mixture was carefully filtered, and the solid was washed with petroleum ether 2-3 times to obtain the products **(R)-2**.

Procedure for kinetic resolution of racemic biaryl oxazepine **1ai:** To a dried 10 mL tube with a stir bar was added the racemic compound **1ai** (0.1 mmol) and anhydrous toluene (2 ml). The mixture was stirred at RT to form a homogeneous solution. Then this solution was cooled to $-10\text{ }^\circ\text{C}$, H_2O (10 μl) and $(R)\text{-C2}$ (10 mol%) was added. After stirring at $-10\text{ }^\circ\text{C}$ for 2 h, the reaction mixture was directly purified by column chromatography to afford the desired chiral products **1ai** and **2ai**.


Scope of the Mitsunobu reaction



Proposed mechanism for Mitsunobu reaction:




Scale-up synthesis of axially chiral biaryl amide 2c



To a dried 50 mL tube with a stir bar was added the PPh₃ (1.57 g, 6.0 mmol), anhydrous toluene (20.0 mL). It was stirred at room temperature to form a homogeneous phase. Then DEAD (1.04 g, 6.0 mmol) was added and the reaction mixture was stirred at room temperature for 2-3 minutes. To the reaction mixture was added (rac)-2c (0.74 g, 2 mmol). The test tube was sealed and stirred at 110 °C for 12 h. Finally, the reaction mixture was directly subjected to the column chromatography (PE/DCM/Et₃N = 80:1:1) to afford 1c (0.71 g, 99% yield). To a dried 100 mL tube with a stir bar was added the (R)-C2 (147.0 mg, 10 mol%), anhydrous cyclohexane (40 ml) and H₂O (100 µl). And then it was stirred at room temperature to form a homogeneous phase. Finally, compound 1c (0.71 g, 2mmol) was added. The test tube was sealed and stirred at room temperature for 3 days. Then the reaction mixture was filtered, and the solid was washed with petroleum ether 2-3 times to afford the product (R)-2c (0.71 g, 95%, 98:2 er).


Synthetic applications

Synthesis of (*R*)-4-chloro-N-(1-(2-phenoxyphenyl)naphthalen-2-yl)benzamide (3)




To a dried 10 mL tube was added compound *(R)*-2c (0.1 mmol, 1.0 equiv), Cu(OAc)₂ (18 mg, 0.1 mmol), phenylboronic acid (36.5 mg, 0.3 mmol) and activated 4Å molecular sieves (100 mg). Then DCM (2.0 mL) and triethylamine (70 µL, 0.5 mmol) was added to the reaction tube, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was subjected to column chromatography (PE/EA = 5/1) to afford product **3** (38 mg, 84% yield, 98:2 er).


Synthesis of ethyl (*R*)-3-(3-(4-chlorobenzamido)-4-(2-hydroxyphenyl)naphthalen-2-yl)acrylate (4)



To a solution of *(R)*-2c (37.4 mg, 0.1 mmol) in TFA and CH₂Cl₂ (v/v = 4:1, 0.5 M) were added ethyl acrylate (44 uL, 4.0 equiv), Pd(OAc)₂ (3.4 mg, 15 mol%), and K₂S₂O₈ (81 mg, 2.0 equiv). The resulting mixture was stirred at RT for 6 h. After the reaction was completed, the reaction mixture was directly subjected to the column chromatography (DCM/EA = 30:1) to afford the desired products **4** (36 mg, 77%, 99:1 er).


Synthesis of (*R*)-4-chloro-N-(1-(2-(phenylethynyl)phenyl)naphthalen-2-yl)benzamide (5)






To a solution of (*R*)-**2c** (37.4 mg, 0.1 mmol) and DMAP (2.6 mg, 20 mol%) in dry DCM (1.3 mL), Et₃N (22 μL, 1.5 equiv) was added at room temperature under N₂ atmosphere. The reaction mixture was stirred at 0 °C for 5 minutes. Tf₂O (22.1 μL, 1.3 equiv) was added dropwise. The resulting reaction mixture was stirred at room temperature for 20 h. Then the mixture solution was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using (PE/DCM = 1/1) to give of **5'** (50.5 mg, 99% yield). To a dried 4 mL tube with a stir bar was added the **5'** (50.5 mg, 0.1 mmol), CuI (20 mol%), n-Bu₄NI (98.7 mg, 3.0 equiv), Pd(PPh₃)₄ (20 mol%), Et₃N and CH₃CN (v/v=1:4, 0.2 ml) under N₂ atmosphere. Then ethynylbenzene (13.6 mg, 1.5 equiv) was added dropwise. The resulting reaction mixture was stirred at 80 °C for 0.5 h and then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (PE/DCM = 5/1) to give product **5** (23.5 mg, 52% yield, 96:4 er).

Synthesis of chiral phosphoric acid catalyst^[4]




To a solution of (*R*)-**6** (0.8 g, 1.35 mmol), (4-((3*r*,5*r*,7*r*)-adamantan-1-yl)phenyl)boronic acid (1.38 g, 5.4 mmol) and Pd(PPh₃)₄ (234 mg, 0.20 mmol) in THF (40 mL) and MeOH (2mL) was added aqueous K₂CO₃ (2 M, 5 mL). The reaction mixture was heated at reflux for 22 h and then the mixture was cooled to ambient temperature, diluted by CH₂Cl₂, washed with brine, dried over Na₂SO₄ and purified by

column chromatography (PE:EA= 15:1) to give (*R*)-**7** (0.66 g, 64% yield) as a white solid.



To a solution of (*R*)-**7** (650 mg, 0.854 mmol) in 6 mL CHCl₃ and 10 mL MeOH, conc. HCl (6.0 mL) was added and the mixture was heated at reflux for 3 h. After cooled to ambient temperature, the mixture was poured into water, extracted by CH₂Cl₂ and the combined organic phase was washed with saturated NaHCO₃ and brine, dried over Na₂SO₄. The solvent was removed, and the residue was purified by chromatography (PE:DCM v/v = 2:1) to give (*R*)-**8** (430 mg, 75% yield) as a white solid.



To a 50 mL oven-dried Schlenk flask containing (*R*)-**8** (430 mg, 0.63 mmol) was added 2 mL anhydrous pyridine and freshly distilled P(O)Cl₃ (193.5 mg, 1.26 mmol) under a nitrogen atmosphere. The mixture was stirred under 90 °C for 12 h. After cooling to room temperature, 2 mL of H₂O was added. The mixture was stirred for another 12 h under 90 °C, then cooled by an ice-bath, followed by slow addition of 16 ml 3N HCl. After stirring for 1 h, the mixture was extracted by CH₂Cl₂ (20 mL × 4). The combined organic layer was concentrated and purified by chromatography on silica gel (first petroleum ether/ethyl acetate = 1:1, then MeOH/CH₂Cl₂ = 1:5) to give white solid. The white solid was dissolved with 45 mL CH₂Cl₂, washed with 3N HCl (25 mL × 3), distilled water (25 mL × 3), and dried under vacuum to give (*R*)-**C2** (410 mg, 87.4% yield).

Mechanism Studies

Detection of the ^{18}O -labeled product via GC-MS





Figure S1. The GC-MS Spectra of ^{18}O -Labeled Product.




Figure S2. The GC-MS Spectra of Products Unlabeled with ^{18}O

Determination of the rotational barriers

The specified biaryl amino phenol (2 mg) was dissolved in toluene (1.0 mL) and heated at indicated temperature. Aliquots (< 0.1 mL) were diluted with $^i\text{PrOH}$ (1.0 mL) and directly analyzed by chiral HPLC to determine the enantiomeric ratio at the specified time. The rotational barrier (ΔG^\ddagger), rate constants for enantiomerization (k_{ent}) and

racemization (k_{rac}), and half-life for racemization ($t_{1/2\text{rac}}$) were calculated based on the following equations,


$$t_{1/2\text{rac}} = \ln 2 / k_{\text{rac}}$$

$$\Delta G^\ddagger = -RT \ln(k_{\text{ent}} h / k_B T)$$

where the transmission coefficient κ is set as 1, Boltzmann constant $k_B = 1.3806503 \times 10^{-23} \text{ J/K}$, Planck constant $h = 6.62606876 \times 10^{-34} \text{ J}\cdot\text{s}$, idea gas constant $R = 8.314472 \text{ J/(mol}\cdot\text{K)}$.^[5]

Table. Change of enantiomer ratio with time for **2c** (120 °C in toluene)

t/s	ee(%)	$\ln(ee_0/ee_t)$
0	95.180	0
3600(1 h)	76.266	0.22154
7200(2 h)	57.542	0.50325
10800(3 h)	40.020	0.86639
14400(4 h)	35.906	0.97486
21600(6 h)	14.370	1.89063
28800(8 h)	7.532	2.53661
36000(10 h)	5.138	2.91911
43200(12 h)	2.348	3.70221



$$\ln(ee_0/ee_t) = 2k_{\text{ent}} t + C$$

$$k_{\text{ent}} = 1/2 \text{ slope} = 0.0000434 \text{ s}^{-1}$$

$$k_{\text{rac}} = 2k_{\text{ent}} = 0.0000868 \text{ s}^{-1}$$

$$t_{1/2\text{rac}} = \ln 2 / k_{\text{rac}} = 7986 \text{ s} = 2.22 \text{ h}$$

$$\Delta G^\ddagger = -RT \ln(k_{\text{ent}} h / k_B T) = 31.1 \text{ kcal/mol}$$

DFT calculations

Conformational sampling

Conformational sampling of the phosphoric acid catalyst was carried out at GFN2-xTB^[6-8] level of theory using the CREST program version 2.12 by Grimme and co-workers.^[9,10] The conformers and rotamers ensemble was generated using the iterative

metadynamics based on genetic z-matrix crossing algorithm (iMTD-GC). Conformers were further optimized at GFN2-xTB level with very tight (*-opt vtight*) optimization. Due to the large size of the phosphoric acid catalyst, the lowest energy conformer was chosen and further optimized at density functional theory (DFT) level and used for the mechanistic studies.

Density functional theory (DFT) calculations

DFT calculations were carried out using the *Gaussian 16* rev. B.01 program.^[11] The global hybrid functional M06-2X^[12] with Karlsruhe basis set of double- ζ valence def2-SVP^[13,14] for all atoms were employed for all gas-phase optimizations. Single point (SP) corrections were performed using M06-2X functional and def2-TZVP^[13] basis set for all atoms. The implicit SMD continuum solvation model^[15] was used to account for the solvent effect of cyclohexane solvent that was used in the experimental reactions. Gibbs energies were evaluated at the room temperature (reaction condition), using the entropic quasi-harmonic treatment scheme of Grimme,^[16] at a cut off frequency of 100 cm⁻¹. The free energies were further corrected using standard concentration of 1 mol/L, which was used in solvation calculations. Data analysis was carried out using the GoodVibes code version 3.1.1.^[16] Gibbs energies evaluated at SMD(cyclohexane)-M06-2X/def2-TZVP//M06-2X/def2-SVP level of theory are given in kcal mol⁻¹ and used for discussion throughout.

Non-covalent interactions (NCIs) were analyzed using NCIPILOT^[17] calculations. The *.wfn* files for NCIPILOT were generated at M06-2X/def2-SVP level of theory. NCI indices calculated with NCIPILOT were visualized at a gradient isosurface value of $s = 0.5$ au. These are colored according to the sign of the second eigenvalue (λ_2) of the Laplacian of the density ($\nabla^2\rho$) over the range of -0.1 (blue = attractive) to +0.1 (red = repulsive). Molecular orbitals are visualized using an isosurface value of 0.05 au throughout. All molecular structures and molecular orbitals were visualized using *PyMOL* software.^[18]

Computational rotational barriers studies

The rotational barriers for the enantiomerization of the substrate **1a** and the addition product **INT3** (Scheme S1) were studied computationally. First, a dihedral angle scan

along the axial C–C carbon bond was performed at M06-2X/def2-SVP in gas phase. The relaxed PES energy profile is shown in Figure S3. This gives an estimate of the rotational barrier of 20.0 kcal mol⁻¹. Using the structure with highest energy on this PES (i.e., structure 4 in Figure S3) as the initial guess structure for TS search, we successfully located the *true* TS for the enantiomerization via rotation along the axial C–C bond. After single point energy correction at higher basis set and with solvent effect at SMD(cyclohexane)-M06-2X/def2-TZVP, substrate **1a** was found to have a rotational barrier/enantiomerization barrier of $\Delta G^\ddagger = 17.4$ kcal mol⁻¹.




Figure S3. Relaxed potential energy surface (PES) scan for the dihedral angle along the C–C axial bond of substrate **1a**, computed at M06-2X/def2-SVP level of theory.

For intermediate **INT3**, we similarly studied the rotational barrier by first performing a dihedral angle scan along the axial C–C bond. The relaxed PES scan for **INT3** is shown in Figure S4. The highest energy structure on the scan PES was used as initial guess structure to locate the true TS for enantiomerization, which has a solvent corrected rotational barrier/enantiomerization barrier of $\Delta G^\ddagger = 24.2$ kcal mol⁻¹ (**TS_rot2**, Figure S5).





Figure S4. Relaxed potential energy surface (PES) scan for the dihedral angle along the C–C axial bond of intermediate **INT3**, computed at M06-2X/def2-SVP level of theory.

Figure S5 shows the DFT optimized structures of the transition states of the enantiomerization of these structures. The TSs for the enantiomerization for each of these structures have been successfully located and verified by intrinsic reaction coordinate (IRC)^[19,20] analyses (see attached IRC movies).



Scheme S1. Computed rotational barriers for the enantiomerization of substrate **1a** and intermediate **INT3**.

TS_rot1	TS_rot2
$\Delta G^\ddagger = 17.4 \text{ kcal mol}^{-1}$	$\Delta G^\ddagger = 24.2 \text{ kcal mol}^{-1}$




Figure S5. DFT-optimized transition state structures for the enantiomerization of substrate **1a** (**TS_rot1**) and intermediate **INT3** (**TS_rot2**). Computed rotational barriers are taken relative to each structure as reference zero. Rotational barriers are calculated at SMD(cyclohexane)-M06-2X/def2-TZVP//M06-2X/def2-SVP level of theory at room temperature and are given in kcal mol⁻¹.

The computed enantiomerization barrier for substrate **1a** at 17.4 kcal mol⁻¹ translates to a half-life of about 1 second at room temperature using simple transition state theory for estimation. Thus, substrate **1a** is expected to enantiomerize rapidly at the reaction condition and no enantiomeric excess (ee) can be observed at the reaction condition. On the other hand, the enantiomerization barrier of 24.2 kcal mol⁻¹ for **INT3** gives a half-life of about 17.5 hours, allowing (*R*)-**INT3** to react away via (*R*)-**TS2** (much lower barrier) more rapidly than it has time to enantiomerize to (*S*)-**INT3** via **TS_rot2** (Figure 3, main text).

We additionally studied the rotational barrier for substrate **1ai**, a relaxed PES dihedral angle scan along the C–C axial axis estimates a rotational barrier of ~60 kcal mol⁻¹ for substrate **1ai** (Figure S6). However, using the highest energy as a guess for TS location, no TS could be successfully located. This is expected and is consistent with previous study of such substrates that the presence of ortho-substituents on the biaryls provide steric hinderance to prevent the ease of enantiomerization via rotation along the C–C axial axis^[21] (the methyl group here provides even more steric hinderance than the hydroxyl group in the earlier study). We further estimated the rotational barrier by using the highest energy structure (structure 3 in Figure S6) directly (without further optimization) and running frequency calculations in gas-phase at M06-2X/def2-SVP

followed by solvent correction at SMD(cyclohexane)-M06-2X/def2-TZVP. This gives an estimated barrier of 62.5 kcal mol⁻¹. Therefore, substrate **1ai** is not expected to racemize under reaction conditions at room temperature (or other synthetically useful temperature, e.g., half-life of 115 days at 400 °C).




Figure S6. Relaxed potential energy surface (PES) scan for the dihedral angle along the C–C axial bond of substrate **1ai**, computed at M06-2X/def2-SVP level of theory.

Similarly, we studied the rotational barriers for the amide product arising from the reaction of substrate **1a**. The relaxed PES scan (Figure S7) suggests that the barriers for enantiomerization are > 30 kcal mol⁻¹, indicating that the product will be enantiostable at room temperature. The direct location of the TS for enantiomerization using the highest energy structures (structures 3 and 6, Figure S7) as initial guesses was unsuccessful; direct frequency calculations using these structures with solvent correction at SMD(cyclohexane)-M06-2X/def2-TZVP estimated the barriers to be 41.8 kcal mol⁻¹ and 34.7 kcal mol⁻¹, respectively, suggesting that the product is enantiostable at room temperature (and may be stable up to 150 °C with a half-life of ~18 hours).











Figure S7. Relaxed potential energy surface (PES) scan for the dihedral angle along the C–C axial bond of the amide product of **2a**, computed at M06-2X/def2-SVP level of theory.

Enantioselectivity determining transition state

From the overall Gibbs energy profile (Figure 3, main text), we see that the enantioselectivity-determining step is the initial phosphoric acid catalyzed addition of water to the bridged biaryl substrate. For each of the enantiomers, (*R*)-**1a** and (*S*)-**1a**, the water molecule can add either to the Re or the Si face of the imine group, giving rise to a total of 4 distinct transition states (TSs). Due to the bulky side groups on the chiral phosphoric acid catalyst, conformational rigidity is determined by the phosphoric acid moiety, which has to be oriented with the imine group in specific spatial arrangement for the catalyzed water addition. This gives rise to only limited conformational freedom in the possible TSs. Figure S8 shows the DFT-optimized TS structures, their HOMO and LUMO plots as well as non-covalent interaction (NCI) plots and their activation barriers relative to substrate **1a**. The frontier molecular orbitals (FMOs) in these TSs have quite similar structure, where the coefficients of the HOMOs are predominantly on the acid catalyst and the coefficients of the LUMOs are predominantly on the substrate. This potentially reflects similar electronic influences in these TSs. The NCI plots suggest that (*R*)-TS-Si may be most favorable as it has the least steric repulsions.

	(R)-TS1-Si	(R)-TS1-Re
ΔG^\ddagger	16.5 kcal mol ⁻¹	27.8 kcal mol ⁻¹
DFT structure		
HOMO		
LUMO		






Figure S8. DFT-optimized TS structures, their HOMOs and LUMOs (isosurface value = 0.05 au) and non-covalent interaction (NCI) plots. Key bond distances are given in Å. Activation barriers (ΔG^\ddagger) are given in kcal mol⁻¹ and taken relative to the starting materials.

Transition state structures for the product formation

The DFT-optimized TS structures for the phosphoric acid catalyzed ring opening of intermediate from the addition of water (most favorable pathway) is shown in Figure S9.

	(R)-TS2	(S)-TS2
ΔG^\ddagger	8.6 kcal mol ⁻¹	9.3 kcal mol ⁻¹




Figure S9. DFT-optimized transition state structures for the acid-catalyzed ring opening of intermediate (R)-INT3. Activation barriers are taken relative to the sum of substrates as reference zero.

Optimized structures and absolute energies, zero-point energies


Geometries of all optimized structures (in .xyz format with their associated energy in Hartrees) and movies of relevant IRC analyses are included in a separate folder named *DFT_structures* with an associated readme.txt file. All these data have been deposited with this Supporting Information and uploaded to zenodo.org (DOI: 10.5281/zenodo.7602173; <https://zenodo.org/record/7602173>).

Absolute values (in Hartrees) for SCF energy, zero-point vibrational energy (ZPE), enthalpy and quasi-harmonic Gibbs free energy for M06-2X/def2-SVP optimized structures and single point corrections in SMD(cyclohexane) using M06-2X/def2-TZVP functional are also included.

Reaction in cyclohexane at room temperature						
Structures	E/au	ZPE/au	H/au	T.S/au	qh-G/au	SP SMD(cyclohe xane) M06- 2X/def2- TZVP
water	-76.323214	0.021594	-76.29784	0.018411	-76.316251	-76.429369
R-C2_cat	-2537.734548	0.904737	-2536.788	0.112701	-2536.891851	-2540.331660
R-1a	-1014.316428	0.318103	-1013.98	0.061097	-1014.038693	-1015.442466

TS_rot1	-1014.288938	0.317502	-1013.9537	0.059473	-1014.011176	-1015.414776
S-1a	-1014.316428	0.318103	-1013.98	0.061097	-1014.038693	-1015.442466
R-INT1-Si	-3628.443719	1.249654	-3627.1316	0.151665	-3627.271814	-3632.238532
R-TS1-Si	-3628.432378	1.249944	-3627.1215	0.147361	-3627.258434	-3632.223761
R-INT2-Si	-3628.466462	1.253748	-3627.1515	0.149859	-3627.289614	-3632.253218
R-TS1-Re	-3628.409266	1.249009	-3627.0991	0.150678	-3627.237514	-3632.203605
S-INT1-Si	-3628.437162	1.248541	-3627.1255	0.155334	-3627.267942	-3632.237811
S-TS1-Si	-3628.421475	1.249543	-3627.1108	0.149913	-3627.248844	-3632.215960
S-INT2-Si	-3628.452169	1.253174	-3627.1376	0.151228	-3627.276462	-3632.245884
S-TS1-Re	-3628.414063	1.250004	-3627.103	0.149414	-3627.24093	-3632.211044
R-INT3	-1090.675017	0.34626	-1090.309	0.064039	-1090.370238	-1091.891815
TS_rot2	-1090.6364	0.345853	-1090.2714	0.062758	-1090.331538	-1091.853314
S-INT3	-1090.676097	0.3467	-1090.3098	0.063627	-1090.370726	-1091.893308
R-INT4	-3628.448013	1.251648	-3627.1348	0.15264	-3627.274171	-3632.240326
R-TS2	-3628.442394	1.248294	-3627.1331	0.149825	-3627.27096	-3632.233872
R-INT5	-3628.470656	1.250559	-3627.1577	0.153929	-3627.298814	-3632.263293
S-INT4	-3628.452779	1.253011	-3627.1384	0.150978	-3627.27698	-3632.244778
S-TS2	-3628.43978	1.247804	-3627.131	0.150125	-3627.268982	-3632.232122
S-INT5	-3628.469607	1.250918	-3627.1563	0.1545	-3627.297551	-3632.263464
R-2a	-1090.690151	0.345055	-1090.3241	0.068524	-1090.388493	-1091.911672

Characterization data of the catalytic reaction products




(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2a): white solid, m.p. = 240-241 °C, 33.5 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.77 (s, 1H), 9.21 (s, 1H), 7.97 (d, *J* = 8.3 Hz, 3H), 7.67 (d, *J* = 7.6 Hz, 2H), 7.59 – 7.38 (m, 6H), 7.32 (t, *J* = 7.9 Hz, 1H), 7.18 (d, *J* = 7.5 Hz, 1H), 7.09 (d, 1H), 6.95 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.5, 155.3, 135.0, 133.8, 132.8, 132.7, 132.1, 131.7, 123.0, 129.7, 129.0, 128.3, 128.0, 127.5, 126.6, 126.3, 125.6, 124.6, 122.6, 119.7, 116.4;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 362.1151, found: 362.1150;

HPLC analysis: 96:4 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 15.6 min, t_{major} = 18.2 min), [α]_D²⁵ = -53.00 (c = 0.2, acetone).



(R)-4-fluoro-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2b): white solid, m.p. = 220-221 °C, 34.9 mg, 98% yield


¹H NMR (500 MHz, DMSO) δ 9.68 (s, 1H), 9.32 (s, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 7.86 (d, *J* = 8.8 Hz, 1H), 7.73 (dd, *J* = 8.6, 5.5 Hz, 2H), 7.50 – 7.47 (m, 1H), 7.46 – 7.41 (m, 2H), 7.31 – 7.26 (m, 3H), 7.14 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.04 (d, *J* = 8.1 Hz, 1H), 6.92 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.1 (d, *J* = 249.8 Hz), 164.7, 155.4, 133.8, 132.8, 132.6, 131.9, 131.6, 130.6, 130.3 (d, *J* = 9.8 Hz), 129.9, 128.4, 128.0, 126.6, 126.5, 125.7, 125.3, 122.8, 119.6, 116.3, 115.9 (d, *J* = 21.8 Hz);

¹⁹F NMR (471 MHz, DMSO) δ -108.7 (s, 1F);

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 380.1057, found: 380.1055;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 18.2 min, t_{major} = 22.9 min), [α]_D²⁵ = +162.00 (c = 0.2, acetone), [α]_D²⁵ = +162.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2c): white solid, m.p. = 250–251 °C, 36.9 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.66 (s, 1H), 9.42 (s, 1H), 7.97 (d, *J* = 8.6 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 1H), 7.69 (d, *J* = 8.5 Hz, 2H), 7.55 – 7.39 (m, 5H), 7.32 – 7.25 (m, 1H), 7.18 – 7.11 (m, 1H), 7.05 (d, *J* = 8.1 Hz, 1H), 6.92 (t, *J* = 7.5 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.8, 155.4, 136.8, 133.8, 133.7, 132.8, 132.6, 131.9, 130.8, 129.9, 129.6, 129.0, 128.3, 128.0, 126.6, 126.5, 125.7, 125.4, 122.8, 119.5, 116.3.

HRMS (ESI, m/z): calcd. for [M+H]⁺ : 374.0942, found: 374.0940;

HPLC analysis: 99:1 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 22.4 min, t_{major} = 26.7 min), $[\alpha]_D^{25}$ = +96.00 (c = 0.2, acetone).




(R)-4-bromo-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2d): white solid, m.p. = 259–260 °C, 41.3 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.65 (s, 1H), 9.42 (s, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 1H), 7.70 – 7.55 (m, 4H), 7.53 – 7.37 (m, 3H), 7.28 (t, *J* = 7.7 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 1H), 7.04 (d, *J* = 8.1 Hz, 1H), 6.91 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.9, 155.4, 134.2, 133.7, 132.8, 132.5, 131.9, 131.8, 130.8, 129.9, 129.7, 128.3, 128.0, 126.6, 126.5, 125.8, 125.7, 125.4, 122.7, 119.5, 116.3;

HRMS (ESI, m/z): calcd. for [M+H]⁺ : 418.0437, found: 418.0433;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 21.6 min, t_{major} = 24.9 min), $[\alpha]_D^{25}$ = -65.00 (c = 0.2, acetone).




(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)-4-methylbenzamide (2e): white solid, m.p. = 249–250 °C, 34.9 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.80 (s, 1H), 9.06 (s, 1H), 8.05 – 7.93 (m, 3H), 7.59 – 7.53 (m, 2H), 7.51 – 7.40 (m, 3H), 7.35 – 7.29 (m, 1H), 7.25 (d, *J* = 7.8 Hz, 2H), 7.17 (dd, *J* = 7.5, 1.8 Hz, 1H), 7.09 (d, *J* = 8.0 Hz, 1H), 6.95 (t, *J* = 7.4 Hz, 1H), 2.34 (s, 3H); **¹³C NMR** (126 MHz, DMSO) δ 165.2, 155.3, 142.2, 133.9, 132.8, 132.7, 132.1, 131.6, 130.0, 129.6, 129.2, 128.3, 128.0, 127.4, 126.6, 126.3, 125.5, 124.3, 122.6, 119.8, 116.4, 21.4;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 376.1308, found: 376.1306;

HPLC analysis: 92:8 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 24.2 min, t_{major} = 26.6 min), [α]_D²⁵ = +116.00 (c = 0.2, acetone).



(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)-4-(trifluoromethyl)benzamide (2f): white solid, m.p. = 239–240 °C, 40.3 mg, 99% yield


¹H NMR (500 MHz, DMSO) δ 9.65 (s, 1H), 9.62 (s, 1H), 7.99 (d, *J* = 8.2 Hz, 2H), 7.92 – 7.74 (m, 5H), 7.52 – 7.46 (m, 3H), 7.28 (t, *J* = 7.8 Hz, 1H), 7.16 (d, *J* = 7.5 Hz, 1H), 7.05 (d, *J* = 8.2 Hz, 1H), 6.92 (t, *J* = 7.6 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.9, 155.4, 139.0, 133.6, 132.8, 132.5, 132.1, 131.8 (q, *J* = 32.0 Hz), 131.4, 129.9, 128.7, 128.6, 128.4, 128.1, 126.6, 126.5, 125.9 (q, *J* = 3.4 Hz), 125.6, 124.3 (q, *J* = 273.0 Hz), 122.8, 119.5, 116.3;

¹⁹F NMR (471 MHz, DMSO) δ -61.3 (s, 3F);

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 430.1025, found: 430.1023;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 16.2 min, t_{major} = 18.2 min), [α]_D²⁵ = -73.50 (c = 0.2, acetone).




(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)-4-nitrobenzamide (2g): white solid, m.p. = 275-276 °C, 38.0 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.79 (s, 1H), 9.58 (s, 1H), 8.28 (d, *J* = 8.3 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.90 (d, *J* = 8.2 Hz, 2H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.52 – 7.46 (m, 3H), 7.27 (t, *J* = 7.9 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.90 (t, *J* = 7.5 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.5, 155.4, 149.5, 140.8, 133.4, 132.8, 132.4, 132.1, 131.8, 129.8, 129.2, 128.3, 128.1, 126.6, 126.5, 125.9, 125.8, 124.0, 122.8, 119.4, 116.2; **HRMS** (ESI, m/z): calcd. for [M+Na]⁺: 407.1002, found: 407.0997;

HPLC analysis: 99:1 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 33.1 min, t_{major} = 35.5 min), $[\alpha]_D^{25}$ = +148.00 (c = 0.2, acetone).




(R)-3-chloro-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2h): white solid, m.p. = 191-192 °C, 36.9 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 9.50 (s, 1H), 7.98 (d, *J* = 8.4 Hz, 2H), 7.82 (d, *J* = 8.8 Hz, 1H), 7.69 – 7.57 (m, 3H), 7.52 – 7.40 (m, 4H), 7.33 – 7.26 (m, 1H), 7.15 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.05 (d, *J* = 8.1 Hz, 1H), 6.95 – 6.89 (m, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.6, 155.4, 137.2, 133.7, 133.6, 132.8, 132.5, 132.0, 131.8, 131.1, 130.9, 129.8, 128.3, 128.0, 127.6, 126.6, 126.5, 126.4, 125.8, 125.5, 122.8, 119.5, 116.2;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 374.0942, found: 374.0942;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 15.9 min, t_{major} = 18.9 min), $[\alpha]_D^{25}$ = +144.00 (c = 0.2, acetone), $[\alpha]_D^{25}$ = +144.00 (c = 0.2, acetone).




(R)-3-bromo-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2i): white solid, m.p. = 211–212 °C, 41.3 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 9.50 (s, 1H), 7.98 (d, *J* = 8.5 Hz, 2H), 7.86 – 7.76 (m, 2H), 7.73 (d, *J* = 7.9 Hz, 1H), 7.67 (d, *J* = 7.7 Hz, 1H), 7.50 – 7.41 (m, 4H), 7.30 (t, *J* = 7.9 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 7.06 (d, *J* = 8.2 Hz, 1H), 6.93 (t, *J* = 7.7 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.5, 155.4, 137.4, 134.7, 133.6, 132.8, 132.5, 132.0, 131.1, 131.0, 130.5, 129.8, 128.3, 128.0, 126.7, 126.6, 126.5, 125.8, 125.5, 122.8, 122.2, 119.5, 116.2;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 418.0437, found: 418.0434;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 17.3 min, t_{major} = 20.6 min), [α]_D²⁵ = −54.50 (c = 0.2, acetone).




(R)-2-chloro-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)benzamide (2j): white solid, m.p. = 228–229 °C, 36.9 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.51 (s, 1H), 9.44 (s, 1H), 7.98 (t, *J* = 8.1 Hz, 2H), 7.90 (d, *J* = 8.8 Hz, 1H), 7.52 – 7.39 (m, 5H), 7.36 – 7.31 (m, 3H), 7.15 (d, *J* = 7.5 Hz, 1H), 7.04 (d, *J* = 8.2 Hz, 1H), 6.96 (t, *J* = 7.5 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.4, 155.7, 136.8, 133.5, 132.9, 132.6, 131.8, 131.6, 130.7, 130.4, 130.2, 129.8, 129.6, 128.3, 128.0, 127.5, 126.6, 126.5, 125.8, 125.1, 122.8, 119.5, 116.2;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 374.0942, found: 374.0940;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 23.2 min, t_{major} = 26.4 min), [α]_D²⁵ = −102.50 (c = 0.2, acetone).




(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)furan-2-carboxamide(2k): white solid, m.p. = 170–171 °C, 32.6 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.91 (s, 1H), 8.85 (s, 1H), 8.15 (d, *J* = 8.8 Hz, 1H), 7.98 – 7.94 (m, 2H), 7.81 – 7.78 (m, 1H), 7.50 – 7.33 (m, 4H), 7.19 – 7.10 (m, 3H), 7.04 – 6.96 (m, 1H), 6.65 (dd, *J* = 3.5, 1.8 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 155.8, 155.1, 147.4, 145.9, 132.8, 132.5, 132.4, 131.1, 130.0, 128.1, 127.9, 127.5, 126.5, 125.9, 125.2, 122.6, 121.7, 119.7, 116.2, 115.1, 112.7;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 352.0944, found: 352.0942;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 18.4 min, t_{major} = 22.2 min), [α]_D²⁵ = -110.50 (c = 0.2, acetone).




(R)-N-(1-(2-hydroxyphenyl)naphthalen-2-yl)thiophene-2-carboxamide (2l): white solid, m.p. = 240–241 °C, 34.1 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.75 (s, 1H), 9.19 (s, 1H), 8.00 – 7.94 (m, 2H), 7.90 (d, *J* = 8.8 Hz, 1H), 7.81 (dd, *J* = 5.0, 1.2 Hz, 1H), 7.53 – 7.47 (m, 2H), 7.45 – 7.40 (m, 2H), 7.33 – 7.27 (m, 1H), 7.18 – 7.11 (m, 2H), 7.07 (dd, *J* = 8.2, 1.2 Hz, 1H), 6.97 – 6.90 (m, 1H);

¹³C NMR (126 MHz, DMSO) δ 160.2, 155.3, 139.9, 133.4, 132.8, 132.7, 132.0, 131.7, 130.0, 129.9, 129.0, 128.6, 128.3, 128.1, 126.6, 126.4, 125.7, 124.7, 122.5, 119.7, 116.4;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 368.0716, found: 368.0715;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 18.1 min, t_{major} = 21.5 min), [α]_D²⁵ = -114.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxy-5-methylphenyl)naphthalen-2-yl)benzamide (2m):
white solid, m.p. = 189–190 °C, 35.6 mg, 92% yield

¹H NMR (500 MHz, DMSO) δ 9.51 (s, 1H), 9.36 (s, 1H), 7.96 (d, *J* = 7.3 Hz, 2H), 7.88 (d, *J* = 8.8 Hz, 1H), 7.69 (d, *J* = 8.5 Hz, 2H), 7.54 (d, *J* = 8.5 Hz, 2H), 7.51 – 7.47 (m, 2H), 7.45 – 7.40 (m, 1H), 7.10 (dd, *J* = 8.3, 2.2 Hz, 1H), 6.96 (t, 2H), 2.21 (s, 3H);
¹³C NMR (126 MHz, DMSO) δ 164.8, 153.0, 136.9, 133.9, 133.6, 132.9, 132.8, 131.9, 130.4, 130.3, 129.5, 129.1, 128.3, 128.0, 127.9, 126.6, 126.5, 125.7, 125.0, 122.4, 116.3, 20.6;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 410.0918, found: 410.0917;

HPLC analysis: 96.5:3.5 er, (CHIRALCEL IF column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major} = 17.4 min, t_{minor} = 22.5 min), $[\alpha]_D^{25}$ = +108.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(5-ethyl-2-hydroxyphenyl)naphthalen-2-yl)benzamide(2n):
white solid, m.p. = 187–188 °C, 36.5 mg, 91% yield

¹H NMR (500 MHz, DMSO) δ 9.50 (s, 1H), 9.43 (s, 1H), 7.98 (d, *J* = 8.4 Hz, 2H), 7.88 (d, *J* = 8.8 Hz, 1H), 7.71 (d, *J* = 8.1 Hz, 2H), 7.54 (d, *J* = 8.3 Hz, 2H), 7.52 – 7.48 (m, 2H), 7.44 (dd, *J* = 8.7, 6.4 Hz, 1H), 7.13 (dd, *J* = 8.2, 2.2 Hz, 1H), 7.01 – 6.97 (m, 2H), 2.53 – 2.48 (q, *J* = 7.5 Hz, 2H), 1.08 (t, *J* = 7.5 Hz, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.5, 152.9, 136.5, 134.2, 133.5, 133.3, 132.4, 131.5, 131.2, 130.6, 129.2, 128.8, 128.6, 128.0, 127.6, 126.4, 126.2, 125.4, 125.0, 122.1, 115.9, 27.4, 16.0;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 424.1075, found: 424.1072;

HPLC analysis: 95:5 er, (CHIRALCEL IF column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major} = 18.2 min, t_{minor} = 22.5 min), $[\alpha]_D^{25}$ = -55.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(2-hydroxy-5-vinylphenyl)naphthalen-2-yl)benzamide(2o):


white solid, m.p. = 179–180 °C, 37.9 mg, 95% yield

¹H NMR (500 MHz, DMSO) δ 9.82 (s, 1H), 9.48 (s, 1H), 7.98 (d, *J* = 8.5 Hz, 2H), 7.82 (d, *J* = 8.5 Hz, 1H), 7.68 (d, *J* = 8.1 Hz, 2H), 7.51 (d, *J* = 8.0 Hz, 3H), 7.47 – 7.43 (m, 2H), 7.40 (d, *J* = 8.7 Hz, 1H), 7.26 (s, 1H), 7.00 (d, *J* = 8.5 Hz, 1H), δ 6.62 (dd, *J* = 17.5, 11.0 Hz, 1H), 5.57 (d, *J* = 17.5 Hz, 1H), 5.04 (d, *J* = 11.0 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.0, 155.5, 136.8, 136.7, 133.9, 133.8, 132.8, 132.0, 130.7, 130.6, 129.6, 129.0, 128.8, 128.4, 128.1, 127.7, 126.7, 126.5, 125.8, 125.6, 122.9, 116.4, 111.7;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 422.0918, found: 422.0915;

HPLC analysis: 93:7 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 21.3 min, t_{major} = 26.5 min), [α]_D²⁵ = +106.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(4-hydroxy-[1,1'-biphenyl]-3-yl)naphthalen-2-yl)benzamide(2p):


white solid, m.p. = 215–216 °C, 44.4 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.80 (s, 1H), 9.65 (s, 1H), 7.99 (dd, *J* = 8.5, 4.5 Hz, 2H), 7.80 (d, *J* = 8.7 Hz, 1H), 7.72 (d, *J* = 8.4 Hz, 2H), 7.60 (dd, *J* = 8.5, 2.4 Hz, 1H), 7.54 (dd, *J* = 8.5, 3.3 Hz, 3H), 7.49 (dd, *J* = 8.2, 6.3 Hz, 3H), 7.46 – 7.42 (m, 2H), 7.36 (t, *J* = 7.6 Hz, 2H), 7.24 (t, *J* = 7.4 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.2, 155.3, 140.4, 136.8, 133.9, 133.8, 132.8, 132.1, 131.5, 131.4, 130.7, 129.7, 129.3, 128.9, 128.4, 128.2, 128.1, 127.0, 126.7, 126.6, 126.5, 126.1, 125.9, 123.4, 116.8;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 472.1075, found: 472.1070;

HPLC analysis: 93:7 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 26.5 min, t_{major} = 33.4 min), [α]_D²⁵ = +145.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxy-5-methoxyphenyl)naphthalen-2-yl)benzamide(2q):
white solid, m.p. = 139-140 °C, 39.5 mg, 98% yield

¹H NMR (500 MHz, DMSO) δ 9.46 (s, 1H), 9.24 (s, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 7.83 (d, *J* = 8.8 Hz, 1H), 7.71 (d, *J* = 8.0 Hz, 2H), 7.54 (d, *J* = 8.2 Hz, 2H), 7.50 (d, *J* = 8.6 Hz, 2H), 7.45 (d, *J* = 7.7 Hz, 1H), 6.96 (d, *J* = 8.8 Hz, 1H), 6.88 (d, *J* = 9.0 Hz, 1H), 6.71 (s, 1H), 3.62 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.9, 152.4, 149.1, 136.9, 133.8, 133.7, 132.7, 131.9, 130.7, 129.6, 129.1, 128.4, 128.1, 126.7, 126.6, 125.8, 125.4, 123.3, 117.2, 117.0, 115.6, 55.8;

HRMS (ESI, m/z): calcd. for [M+Na]⁺:426.0867, found: 426.0867;

HPLC analysis: 96:4 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major} = 26.1 min, t_{minor} = 30.3 min), [α]_D²⁵ = +32.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(2-hydroxy-5-(trifluoromethyl)phenyl)naphthalen-2-yl)benzamide(2r): white solid, m.p. = 195-196 °C, 39.7 mg, 90% yield


¹H NMR (500 MHz, DMSO) δ 10.40 (s, 1H), 9.85 (s, 1H), 8.01 (t, *J* = 7.7 Hz, 2H), 7.69 (dd, *J* = 11.3, 8.5 Hz, 3H), 7.60 (dd, *J* = 8.7, 2.4 Hz, 1H), 7.51 (dd, *J* = 7.9, 5.7 Hz, 3H), 7.48 – 7.44 (m, 2H), 7.41 (d, *J* = 8.4 Hz, 1H), 7.15 (d, *J* = 8.6 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.5, 159.1, 136.7, 134.1, 133.8, 132.4, 132.1, 131.1, 129.8, 129.5 (q, *J* = 7.3 Hz), 128.8, 128.7, 128.5, 127.0, 126.9, 126.8, 126.2, 126.1, 125.2 (q, *J* = 271.3 Hz), 123.8, 119.8 (q, *J* = 31.8 Hz), 116.6;

¹⁹F NMR (471 MHz, DMSO) δ -59.5 (s, 3F);

HRMS (ESI, m/z): calcd. for [M+Na]⁺:464.0636, found: 464.0630;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major} = 11.8 min, t_{minor} = 13.8 min), [α]_D²⁵ = -60.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxy-4-methoxyphenyl)naphthalen-2-yl)benzamide(2s):
white solid, m.p. = 209–210 °C, 37.4 mg, 93% yield

¹H NMR (500 MHz, DMSO) δ 9.74 (s, 1H), 9.36 (s, 1H), 7.95 – 7.86 (m, 3H), 7.73 (d, *J* = 8.1 Hz, 2H), 7.60 – 7.37 (m, 5H), 7.06 (d, *J* = 8.3 Hz, 1H), 6.62 (s, 1H), 6.57 – 6.48 (m, 1H), 3.76 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.7, 160.6, 156.3, 136.9, 133.9, 133.8, 133.2, 133.1, 131.9, 130.2, 129.6, 129.1, 128.2, 127.8, 126.6, 126.5, 125.6, 125.0, 115.1, 105.4, 102.0, 55.5;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 426.0867, found: 426.0864;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 26.2 min, t_{major} = 31.0 min), $[\alpha]_D^{25} = -84.00$ (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxy-3-methylphenyl)naphthalen-2-yl)benzamide(2t):
white solid, m.p. = 217–218 °C, 36.7 mg, 95% yield

¹H NMR (500 MHz, DMSO) δ 9.36 (s, 1H), 7.98 (dd, *J* = 8.5, 5.9 Hz, 2H), 7.90 (d, *J* = 8.8 Hz, 1H), 7.66 (t, *J* = 8.3 Hz, 2H), 7.53 (d, *J* = 8.3 Hz, 2H), 7.51 – 7.47 (m, 1H), 7.45 – 7.39 (m, 2H), 7.23 – 7.17 (m, 1H), 6.95 (dd, *J* = 7.5, 1.8 Hz, 1H), 6.87 (t, *J* = 7.4 Hz, 1H), 2.28 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.9, 153.1, 136.9, 133.9, 133.8, 133.0, 131.9, 131.3, 130.4, 130.0, 129.6, 129.1, 128.4, 128.2, 126.7, 126.5, 126.0, 125.8, 125.0, 123.7, 120.2, 17.4;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 410.0918, found: 410.0913;

HPLC analysis: 96.5:3.5 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 9.2 min, t_{major} = 15.4 min), $[\alpha]_D^{25} = -74.50$ (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxy-3-methoxyphenyl)naphthalen-2-yl)benzamide(2u):
white solid, m.p. = 159–160 °C, 38.6 mg, 96% yield

¹H NMR (500 MHz, DMSO) δ 9.35 (s, 1H), 8.83 (s, 1H), 7.97 (dd, *J* = 8.5, 3.2 Hz, 2H), 7.86 (d, *J* = 8.8 Hz, 1H), 7.69 (dd, *J* = 8.5, 2.3 Hz, 2H), 7.55 – 7.38 (m, 5H), 7.06 (dd, *J* = 8.2, 1.5 Hz, 1H), 6.89 (t, *J* = 7.9 Hz, 1H), 6.77 – 6.72 (m, 1H), 3.87 (s, 3H);
¹³C NMR (126 MHz, DMSO) δ 164.8, 148.3, 144.5, 136.8, 133.8, 133.6, 132.7, 131.8, 130.2, 129.6, 129.0, 128.3, 128.0, 126.6, 126.5, 125.7, 125.2, 123.9, 123.0, 119.5, 111.9, 56.3;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 426.0867, found: 426.0864;

HPLC analysis: 99:1 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 30.5 min, t_{major} = 51.9 min), [α]_D²⁵ = +32.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(3-fluoro-2-hydroxyphenyl)naphthalen-2-yl)benzamide(2v):
white solid, m.p. = 219–220 °C, 38.3 mg, 98% yield


¹H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 9.58 (s, 1H), 7.99 (dd, *J* = 8.5, 4.9 Hz, 2H), 7.76 (d, *J* = 8.7 Hz, 1H), 7.71 (d, *J* = 8.1 Hz, 2H), 7.55 – 7.48 (m, 3H), 7.48 – 7.38 (m, 2H), 7.29 – 7.20 (m, 1H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.92 – 6.85 (m, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.2, 152.3 (d, *J* = 239.0 Hz), 143.3 (d, *J* = 14.4 Hz), 136.8, 134.0, 133.8, 132.6, 132.0, 130.3 (d, *J* = 2.6 Hz), 129.8, 128.9, 128.4 (d, *J* = 4.0 Hz), 127.7 (d, *J* = 2.8 Hz), 126.8, 126.5 (d, *J* = 2.9 Hz), 126.3, 126.1, 125.9, 119.5 (d, *J* = 7.3 Hz), 116.0, 115.8;

¹⁹F NMR (471 MHz, DMSO) δ -135.0 (s, 1F);

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 414.0668, found: 414.0664;

HPLC analysis: 99:1 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 26.3 min, t_{major} = 28.3 min), [α]_D²⁵ = +28.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(3-chloro-2-hydroxyphenyl)naphthalen-2-yl)benzamide(2w):


white solid, m.p. = 231–232 °C, 40.3 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.69 (s, 1H), 9.17 (s, 1H), 8.00 (dd, *J* = 8.7, 6.8 Hz, 2H), 7.75 (d, *J* = 8.8 Hz, 1H), 7.70 (d, *J* = 8.5 Hz, 2H), 7.55 – 7.49 (m, 3H), 7.48 – 7.42 (m, 2H), 7.37 (d, *J* = 8.4 Hz, 1H), 7.08 (dd, *J* = 7.6, 1.7 Hz, 1H), 6.94 (t, *J* = 7.8 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.4, 151.2, 136.8, 134.1, 133.8, 132.6, 132.0, 131.1, 130.6, 130.0, 129.8, 128.9, 128.6, 128.4, 126.9, 126.3, 126.2, 126.1, 126.0, 121.7, 120.8;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 430.0372, found: 430.0369;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 23.6 min, t_{major} = 27.9 min), [α]_D²⁵ = +61.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1'-hydroxy-[1,2'-binaphthalen]-2-yl)benzamide(2x):


white solid, m.p. = 228–229 °C, 41.0 mg, 97% yield

¹H NMR (500 MHz, DMSO) δ 9.59 (s, 1H), 9.25 (s, 1H), 8.31 (q, 1H), 8.02 (dd, *J* = 11.4, 8.5 Hz, 2H), 7.89 (t, *J* = 7.2 Hz, 2H), 7.70 – 7.63 (m, 2H), 7.57 – 7.47 (m, 4H), 7.46 – 7.38 (m, 4H), 7.22 (d, *J* = 8.3 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 165.2, 150.6, 136.8, 134.7, 134.4, 133.7, 133.0, 132.1, 130.6, 130.0, 129.7, 128.9, 128.5, 128.4, 128.1, 126.8, 126.7, 126.5, 126.0, 125.8, 125.7, 125.6, 122.9, 119.8, 117.7;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 446.0918, found: 446.0914;

HPLC analysis: 96:4 er ee, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major} = 27.29 min, t_{minor} = 29.06 min), [α]_D²⁵ = −94.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(1-hydroxydibenzo[b,d]furan-2-yl)naphthalen-2-yl)benzamide (2y): white solid, m.p. = 247–248 °C, 45.8 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.66 (s, 1H), 9.41 (s, 1H), 8.17 (d, *J* = 7.4 Hz, 1H), 8.06 – 7.96 (m, 2H), 7.90 (d, *J* = 8.6 Hz, 1H), 7.68 (d, *J* = 8.6 Hz, 3H), 7.54 – 7.36 (m, 7H), 7.32 – 7.16 (m, 2H);

¹³C NMR (126 MHz, DMSO) δ 165.4, 157.1, 155.4, 151.4, 136.7, 134.9, 133.8, 133.4, 132.1, 131.4, 129.7, 128.8, 128.6, 128.6, 128.5, 126.9, 126.8, 126.3, 125.8, 125.7, 123.8, 123.5, 123.0, 118.1, 113.8, 111.7, 103.8;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 464.1048, found: 464.1044;

HPLC analysis: 93:7 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=16.86 min, t_{major}=26.54 min), [α]_D²⁵ = +65.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxyphenyl)-7-methoxynaphthalen-2-yl)benzamide (2z): white solid, m.p. = 171–172 °C, 39.8 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.69 (s, 1H), 9.35 (s, 1H), 7.90 (dd, *J* = 8.9, 4.1 Hz, 2H), 7.69 (t, *J* = 9.2 Hz, 3H), 7.52 (d, *J* = 8.2 Hz, 2H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.21 – 7.14 (m, 2H), 7.05 (d, *J* = 8.1 Hz, 1H), 6.92 (t, *J* = 7.4 Hz, 1H), 6.79 (d, *J* = 2.6 Hz, 1H), 3.64 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.6, 157.7, 155.3, 136.8, 134.2, 134.1, 133.8, 132.5, 130.0, 129.9, 129.5, 129.4, 129.0, 127.8, 127.3, 122.9, 122.8, 119.6, 117.5, 116.4, 105.6, 55.3;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 426.0867, found: 426.0865;

HPLC analysis: 96:4 er, (CHIRALCEL OD column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}=10.76 min, t_{minor}=12.32 min), [α]_D²⁵ = -58.00 (c = 0.2, acetone).



(R)-N-(7-(benzyloxy)-1-(2-hydroxyphenyl)naphthalen-2-yl)-4-chlorobenzamide


(2aa): white solid, m.p. = 162–163 °C, 47.4 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.68 (s, 1H), 9.34 (s, 1H), 7.90 (t, *J* = 8.9 Hz, 2H), 7.74 – 7.62 (m, 3H), 7.55 – 7.48 (m, 2H), 7.37 – 7.27 (m, 6H), 7.25 (dd, *J* = 8.9, 2.5 Hz, 1H), 7.09 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.06 (dd, *J* = 8.2, 1.1 Hz, 1H), 6.96 – 6.85 (m, 2H), δ 5.00 (d, *J* = 11.5 Hz, 2H);

¹³C NMR (126 MHz, DMSO) δ 164.6, 156.7, 155.2, 137.1, 136.8, 134.2, 134.1, 133.8, 132.5, 130.0, 129.8, 129.5, 129.4, 129.0, 128.9, 128.4, 128.4, 128.3, 127.7, 127.4, 122.8, 119.6, 117.8, 116.4, 107.3, 69.7;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 502.1180, found: 502.1177;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=19.5 min, t_{major}=25.1 min), [α]_D²⁵ = -108.00 (c = 0.2, acetone).



(R)-N-(6-bromo-1-(2-hydroxyphenyl)naphthalen-2-yl)-4-chlorobenzamide(2ab):


white solid, m.p. = 95–96 °C, 40.6 mg, 90% yield

¹H NMR (500 MHz, DMSO) δ 8.23 (t, *J* = 1.5 Hz, 1H), 7.99 – 7.91 (m, 2H), 7.76 (d, *J* = 8.6 Hz, 2H), 7.55 (d, *J* = 1.2 Hz, 2H), 7.35 (d, *J* = 8.3 Hz, 2H), 7.19 – 7.14 (m, 1H), 7.08 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.03 (dd, *J* = 8.3, 1.2 Hz, 1H), 6.78 – 6.72 (m, 1H);

¹³C NMR (126 MHz, DMSO) δ 163.8, 158.4, 136.5, 134.3, 133.3, 132.8, 132.7, 131.4, 130.5, 129.7, 129.5, 129.2, 128.9, 128.8, 128.6, 126.4, 125.5, 122.6, 118.4, 117.5, 116.8.

HRMS (ESI, m/z): calcd. for [M+H]⁺: 452.0047, found: 452.0041;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=19.4 min, t_{major}=32.3 min), [α]_D²⁵ = -54.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxyphenyl)-6-methoxynaphthalen-2-yl)benzamide(2ac):
white solid, m.p. = 209–210 °C, 39.8 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.65 (s, 1H), 9.41 (s, 1H), 7.87 (d, *J* = 8.8 Hz, 1H), 7.74 (d, *J* = 8.8 Hz, 1H), 7.69 (d, *J* = 8.2 Hz, 2H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 2.6 Hz, 1H), 7.36 (d, *J* = 9.2 Hz, 1H), 7.27 (td, *J* = 7.7, 1.7 Hz, 1H), 7.13 (d, *J* = 7.5 Hz, 1H), 7.10 (dd, *J* = 9.2, 2.6 Hz, 1H), 7.03 (d, *J* = 8.1 Hz, 1H), 6.89 (t, *J* = 7.4 Hz, 1H), 3.89 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.8, 157.3, 155.3, 136.7, 133.9, 133.3, 132.5, 131.6, 131.3, 129.7, 129.6, 128.9, 128.2, 128.0, 126.8, 126.2, 123.0, 119.4, 119.0, 116.2, 106.6, 55.7;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 404.1048, found: 404.1044;

HPLC analysis: 96:4 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=28.6 min, t_{major}=38.8 min), [α]_D²⁵ = -98.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxyphenyl)-6-phenylnaphthalen-2-yl)benzamide(2ad):
white solid, m.p. = 219–220 °C, 42.2 mg, 94% yield

¹H NMR (500 MHz, DMSO) δ 9.73 (s, 1H), 9.43 (s, 1H), 8.28 (d, *J* = 1.9 Hz, 1H), 8.06 (d, *J* = 8.8 Hz, 1H), 7.88 (d, *J* = 8.8 Hz, 1H), 7.84 – 7.80 (m, 2H), 7.78 (dd, *J* = 8.9, 2.0 Hz, 1H), 7.70 (d, *J* = 8.5 Hz, 2H), 7.55 – 7.51 (m, 5H), 7.40 (t, *J* = 7.3 Hz, 1H), 7.30 (td, *J* = 7.8, 1.7 Hz, 1H), 7.18 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.06 (d, *J* = 8.2 Hz, 1H), 6.93 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.8, 155.4, 140.3, 137.3, 136.9, 133.9, 133.8, 132.6, 132.2, 132.1, 130.6, 130.0, 129.6, 129.5, 129.0, 128.4, 128.1, 127.4, 127.3, 125.8, 125.7, 122.7, 119.6, 116.4;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 450.1255, found: 450.1250;

HPLC analysis: 97:3 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=34.01 min, t_{major}=36.19), [α]_D²⁵ = +87.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-hydroxyphenyl)anthracen-2-yl)benzamide(2ae): yellow solid, m.p. = 251–252 °C, 41.8 mg, 99% yield

¹H NMR (500 MHz, DMSO) δ 9.74 (s, 1H), 9.46 (s, 1H), 8.64 (s, 1H), 8.15 (d, *J* = 9.1 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 8.05 (s, 1H), 7.89 – 7.84 (m, 2H), 7.72 (d, *J* = 8.1 Hz, 2H), 7.57 – 7.42 (m, 4H), 7.35 (t, *J* = 7.8 Hz, 1H), 7.24 (d, *J* = 7.5 Hz, 1H), 7.11 (d, *J* = 8.2 Hz, 1H), 6.98 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.8, 155.5, 136.9, 133.7, 133.1, 132.6, 131.6, 131.2, 131.1, 130.3, 130.0, 129.9, 129.6, 129.0, 128.6, 128.3, 128.2, 126.7, 126.2, 126.0, 125.6, 124.9, 122.8, 119.7, 116.5;

HRMS (ESI, m/z): calcd. for [M+Na]⁺:446.0918, found: 446.0915;

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor}=19.4 min, t_{major}=21.9 min), [α]_D²⁵ = −74.00 (c = 0.2, acetone).




(R)-N-(2'-hydroxy-6-methyl-[1,1'-biphenyl]-2-yl)-4-nitrobenzamide(2af): yellow solid, m.p. = 149–150 °C, 34.4 mg, 99% yield

¹H NMR (500 MHz, CDCl₃) δ 8.25 (d, *J* = 8.2 Hz, 1H), 8.20 – 8.07 (m, 2H), 7.78 (s, 1H), 7.57 (d, *J* = 8.7 Hz, 2H), 7.44 – 7.38 (m, 1H), 7.35 (t, *J* = 7.9 Hz, 1H), 7.17 – 7.07 (m, 4H), 5.49 (s, 1H), 2.12 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 163.1, 153.2, 149.6, 140.0, 138.6, 135.8, 130.8, 130.6, 129.4, 127.9, 127.1, 126.4, 123.9, 121.9, 121.7, 118.9, 116.7, 20.3;

HRMS (ESI, m/z): calcd. for [M+Na]⁺:371.1002, found: 371.0999;

HPLC analysis: 94:6 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}=16.3 min, t_{minor}=22.0min), [α]_D²⁵ = +112.00 (c = 0.2, acetone).




(S)-N-(6-chloro-2'-hydroxy-[1,1'-biphenyl]-2-yl)-4-nitrobenzamide (2ag): white solid, m.p. = 190–191 °C, 36.1 mg, 98% yield

¹H NMR (500 MHz, DMSO) δ 9.69 (s, 1H), 9.66 (s, 1H), 8.25 (d, *J* = 8.5 Hz, 2H), 7.81 (d, *J* = 8.5 Hz, 2H), 7.60 (d, *J* = 7.8 Hz, 1H), 7.50 – 7.40 (m, 2H), 7.22 – 7.16 (m, 1H), 7.08 (dd, *J* = 7.6, 1.6 Hz, 1H), 6.93 (d, *J* = 8.1 Hz, 1H), 6.83 (t, *J* = 7.4 Hz, 1H);

¹³C NMR (126 MHz, DMSO) δ 164.3, 154.9, 149.5, 140.6, 137.9, 134.5, 134.2, 131.7, 130.0, 129.2, 129.1, 127.5, 125.8, 124.0, 122.5, 119.1, 116.0;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 371.1002, found: 371.0999;

HPLC analysis: 95:5 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}=16.3 min, t_{minor}=22.4 min), [α]_D²⁵ = -48.00 (c = 0.2, acetone).



2ah


(R)-4-chloro-N-(2-(2-hydroxynaphthalen-1-yl)phenyl)benzamide (2ah): white solid, m.p. = 180–181 °C, 34.4 mg, 92% yield

¹H NMR (500 MHz, DMSO) δ 8.99 (s, 1H), 7.94 (d, *J* = 8.1 Hz, 1H), 7.83 (t, *J* = 8.2 Hz, 2H), 7.53 – 7.44 (m, 1H), 7.39 (s, 4H), 7.36 – 7.22 (m, 7H);

¹³C NMR (126 MHz, DMSO) δ 164.4, 152.5, 137.0, 136.6, 134.1, 133.7, 132.8, 130.5, 130.0, 129.3, 128.9, 128.6, 128.5, 128.1, 126.8, 125.4, 125.2, 124.7, 123.1, 118.7, 117.4;

HRMS (ESI, m/z): calcd. for [M+Na]⁺ : 396.0762, found: 396.0761;

HPLC analysis: 92:8 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{minor} = 16.9 min, t_{major} = 21.3 min), [α]_D²⁵ = +100.00 (c = 0.2, acetone).



(R)-4-chloro-N-(1-(2-hydroxy-4,6-dimethylphenyl)naphthalen-2-yl)benzamide


(2ai): white solid, m.p. = 190–192 °C, 39.7 mg, 99% yield; For kinetic resolution: 49% yield.

¹H NMR (500 MHz, DMSO) δ 9.16 (s, 1H), 8.97 (s, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.96 (d, *J* = 8.5 Hz, 2H), 7.63 (d, *J* = 8.5 Hz, 2H), 7.53 (d, *J* = 8.5 Hz, 2H), 7.49 – 7.44 (m, 1H), 7.42 – 7.37 (m, 1H), 7.26 (d, *J* = 8.4 Hz, 1H), 6.68 (d, *J* = 13.3 Hz, 2H), 2.28 (s, 3H), 1.75 (s, 3H);

¹³C NMR (126 MHz, DMSO) δ 164.7, 155.6, 138.8, 138.7, 136.9, 134.1, 134.0, 132.7, 131.7, 129.6, 129.1, 128.5, 128.3, 127.8, 126.7, 125.8, 125.6, 124.2, 122.4, 119.2, 114.3, 21.5, 20.1;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 424.1075, found: 424.1072;

HPLC analysis: 51:49 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}=14.6 min, t_{minor}=17.7 min), [α]_D²⁵ = +50.00 (c = 0.2, acetone); For kinetic resolution: 95:5 er, [α]_D²⁵ = +162.00 (c = 0.2, acetone).




(R)-4-chloro-N-(1-(2-phenoxyphenyl)naphthalen-2-yl)benzamide (3): white solid, m.p. = 131–132 °C, 76.0 mg, 84% yield

¹H NMR (500 MHz, DMSO) δ 9.74 (s, 1H), 7.96 (t, *J* = 8.5 Hz, 2H), 7.74 (d, *J* = 8.3 Hz, 2H), 7.69 (d, *J* = 8.7 Hz, 1H), 7.54 (dd, *J* = 8.7, 2.4 Hz, 3H), 7.51 – 7.43 (m, 2H), 7.43 – 7.36 (m, 2H), 7.23 (t, *J* = 7.5 Hz, 1H), 7.19 (t, *J* = 7.8 Hz, 2H), 6.98 (t, *J* = 7.4 Hz, 1H), 6.91 (d, *J* = 8.2 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 2H);

¹³C NMR (126 MHz, DMSO) δ 165.2, 156.5, 155.4, 136.8, 134.1, 133.9, 133.4, 132.7, 132.0, 130.7, 130.2, 130.1, 129.9, 128.9, 128.5, 128.4, 127.1, 126.8, 126.3, 126.1, 126.0, 123.9, 123.4, 119.5, 118.1;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 450.1255, found: 450.1244);

HPLC analysis: 98:2 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}= 22.2 min, t_{minor}= 58.5 min), [α]_D²⁵ = +150.00 (c = 0.2, acetone).




Ethyl(R,E)-3-(3-(4-chlorobenzamido)-4-(2-hydroxyphenyl)naphthalen-2-yl)acrylate (4) : white solid, m.p. = 109-110 °C, 36.0 mg, 77% yield

¹H NMR (500 MHz, DMSO) δ 9.96 (s, 1H), 9.49 (s, 1H), 8.64 (s, 1H), 8.08 (d, *J* = 8.0 Hz, 1H), 7.87 (d, *J* = 16.0 Hz, 1H), 7.69 (d, *J* = 8.5 Hz, 2H), 7.62 – 7.56 (m, 1H), 7.54 (d, *J* = 8.5 Hz, 2H), 7.52 – 7.47 (m, 1H), 7.42 (d, *J* = 8.5 Hz, 1H), 7.24 (td, *J* = 7.7, 1.8 Hz, 1H), 7.09 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.00 (d, *J* = 8.1 Hz, 1H), δ 6.86 (d, *J* = 3.5 Hz, 1H), 6.83 (d, *J* = 5.5 Hz, 2H), 4.18 (q, *J* = 7.0 Hz, 2H), 1.24 (t, *J* = 7.0 Hz, 3H);

¹³C NMR (126 MHz, DMSO) δ 166.7, 166.1, 155.3, 141.8, 136.8, 136.3, 133.7, 133.5, 132.9, 132.4, 131.6, 131.1, 129.8, 129.6, 129.1, 128.9, 127.7, 127.0, 126.9, 126.9, 123.4, 119.9, 119.1, 115.9, 60.6, 14.6;

HRMS (ESI, m/z): calcd. for [M+H]⁺:472.1310, found: 472.1298;

HPLC analysis: 99:1 er, (CHIRALCEL OD column, *n*-hexane/*i*-PrOH = 80/20, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}= 24.5min, t_{minor}= 26.7min), [α]_D²⁵ = +22.00 (c = 0.2, acetone).



5


(R)-4-chloro-N-(1-(2-(phenylethynyl)phenyl)naphthalen-2-yl)benzamide (5): yellow solid, m.p. = 120-122 °C, 25.8 mg, 52% yield,

¹H NMR (500 MHz, CDCl₃) δ 8.61 (d, *J* = 8.8 Hz, 1H), 8.01 (d, *J* = 8.9 Hz, 1H), 7.91 (d, *J* = 8.1 Hz, 1H), 7.87 – 7.78 (m, 2H), 7.58 – 7.53 (m, 2H), 7.49 (d, *J* = 8.2 Hz, 2H), 7.47 – 7.42 (m, 2H), 7.42 – 7.37 (m, 2H), 7.33 (d, *J* = 8.1 Hz, 2H), 7.17 (d, *J* = 7.2 Hz, 1H), 7.13 (t, *J* = 7.5 Hz, 2H), 6.89 (d, *J* = 7.5 Hz, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 164.2, 138.2, 138.0, 133.4, 133.2, 132.6, 132.5, 131.6, 131.4, 131.1, 129.2, 129.0, 128.9, 128.8, 128.5, 128.3, 128.2, 128.1, 126.6, 126.5, 125.8, 125.1, 124.4, 122.3, 120.7, 93.8, 87.2;

HRMS (ESI, m/z): calcd. for [M+H]⁺:458.1306, found: 458.1294;

HPLC analysis: 96:4 er, (CHIRALCEL OD column, *n*-hexane/*i*-PrOH = 80/20, flow rate = 1.0 mL/min, λ = 254 nm, t_{major}= 16.3min, t_{minor}= 23.7min), [α]_D²⁵ = -116.00 (c = 0.2, acetone).




1,10-bis(4-((3S,5S)-adamantan-1-yl)phenyl)-12-hydroxy-4,5,6,7-tetrahydriindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocine 12-oxide (R)-C2: white solid, m.p. > 300 °C, 410.0 mg, 87.4% yield,

¹H NMR (500 MHz, DMSO) δ 7.39 (d, *J* = 8.5 Hz, 4H), 7.33 – 7.28 (m, 4H), 7.24 (d, *J* = 7.6 Hz, 2H), 7.17 (d, *J* = 7.7 Hz, 2H), 3.16 – 3.06 (m, 2H), 2.85 (dd, *J* = 16.0, 7.5 Hz, 2H), 2.31 (dd, *J* = 12.0, 6.5 Hz, 2H), 2.04 (t, *J* = 3.2 Hz, 6H), 1.85 (d, *J* = 3.0 Hz, 13H), 1.72 (d, *J* = 3.3 Hz, 13H);

¹³C NMR (126 MHz, DMSO) δ 149.5, 145.2, 143.2, 143.1, 141.2, 135.7, 134.3, 130.2, 129.4, 124.7, 122.4, 59.8, 43.1, 39.1, 36.7, 36.0, 28.8;

HRMS (ESI, m/z): calcd. for [M+H]⁺:735.3598, found: 735.3586.




1a

6-phenylbenzo[f]naphtho[2,1-d][1,3]oxazepane (1a): white solid, m.p. = 55-56 °C, 85.0 mg, 88% yield

¹H NMR (500 MHz, CDCl₃) δ 8.43 – 8.37 (m, 2H), 8.31 – 8.26 (m, 1H), 7.94 – 7.87 (m, 2H), 7.79 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.59 – 7.49 (m, 6H), 7.47 – 7.42 (m, 1H), 7.39 – 7.30 (m, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 157.7, 157.3, 142.0, 132.8, 132.2, 132.1, 131.8, 131.4, 129.8, 129.3, 129.2, 128.8, 128.6, 128.4, 127.7, 126.5, 126.4, 126.1, 125.5, 124.9, 121.4; **HRMS** (ESI, m/z): calcd. for [M+H]⁺: 322.1226, found: 322.1224.



1b


6-(4-fluorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1b): white solid, m.p. = 147-148 °C, 97.7 mg, 96% yield

¹H NMR (500 MHz, CDCl₃) δ 8.44 – 8.34 (m, 2H), 8.32 – 8.22 (m, 1H), 7.95 – 7.87 (m, 2H), 7.83 – 7.73 (m, 1H), 7.56 – 7.49 (m, 3H), 7.47 – 7.42 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 2H), 7.19 (t, *J* = 8.7 Hz, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 165.2(d, *J* = 253.4 Hz), 157.6, 156.3, 141.9, 132.9, 132.2, 131.6 (d, *J* = 8.9 Hz), 131.4, 129.9, 129.2, 128.8, 128.4, 127.6, 126.6, 126.4, 126.0, 125.6, 125.0, 121.3, 115.8, 115.7;

¹⁹F NMR (471 MHz, CDCl₃) δ -107.6. (s, 1F);


HRMS (ESI, m/z): calcd. for [M+H]⁺: 340.1132, found: 340.1131.



1c


6-(4-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1c): white solid, m.p. = 183–184 °C, 103.0 mg, 97% yield

¹H NMR (500 MHz, CDCl₃) δ 8.32 (s, 1H), 8.30 (s, 1H), 8.29 – 8.25 (m, 1H), 7.94 – 7.87 (m, 2H), 7.78 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.56 – 7.43 (m, 6H), 7.37 – 7.29 (m, 2H); **¹³C NMR** (126 MHz, CDCl₃) δ 157.5, 156.3, 141.8, 138.1, 132.3, 132.2, 131.4, 130.7, 130.6, 129.9, 129.2, 128.9, 128.8, 128.4, 127.7, 126.6, 126.4, 126.0, 125.6, 125.0, 121.3; **HRMS** (ESI, m/z): calcd. for [M+H]⁺: 356.0837, found: 356.0833.




6-(4-bromophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1d): white solid, m.p. = 164–165 °C, 89.7 mg, 75% yield

¹H NMR (500 MHz, CDCl₃) δ 8.31 – 8.26 (m, 1H), 8.24 (d, *J* = 8.2 Hz, 2H), 7.90 (t, *J* = 8.5 Hz, 2H), 7.78 (d, *J* = 7.7 Hz, 1H), 7.64 (d, *J* = 8.2 Hz, 2H), 7.57 – 7.48 (m, 3H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.33 (q, *J* = 7.8 Hz, 2H); **¹³C NMR** (126 MHz, CDCl₃) δ 157.5, 156.4, 141.8, 132.9, 132.3, 131.9, 131.4, 131.1, 130.7, 129.9, 129.2, 128.9, 128.4, 127.7, 126.7, 126.6, 126.4, 126.0, 125.6, 125.0, 121.3; **HRMS** (ESI, m/z): calcd. for [M+H]⁺: 400.0332, found: 400.0326.



6-(p-tolyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1e): white solid, m.p. = 135–136 °C, 70.3 mg, 70% yield

¹H NMR (500 MHz, CDCl₃) δ 8.32 – 8.25 (m, 3H), 7.93 – 7.88 (m, 2H), 7.79 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.56 (d, *J* = 8.7 Hz, 1H), 7.52 – 7.49 (m, 2H), 7.46 – 7.41 (m, 1H), 7.38 – 7.30 (m, 4H), 2.45 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 157.7, 157.5, 142.4, 142.2, 132.8, 132.7, 132.1, 131.5, 129.7, 129.5, 129.4, 129.3, 128.7, 128.4, 127.6, 126.5, 126.4, 126.1, 125.4, 124.8, 121.4, 21.7; **HRMS** (ESI, m/z): calcd. for [M+Na]⁺: 358.1202, found: 358.1199.




1f

6-(4-(trifluoromethyl)phenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1f): white solid, m.p. = 109-110 °C, 91.0 mg, 78% yield

¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, *J* = 8.1 Hz, 2H), 8.28 (d, *J* = 7.4 Hz, 1H), 7.92 (s, 2H), 7.77 (d, *J* = 9.1 Hz, 3H), 7.54 – 7.45 (m, 4H), 7.34 (d, *J* = 8.5 Hz, 2H);
¹³C NMR (126 MHz, CDCl₃) δ 157.5, 155.7, 141.6, 135.5, 133.0, 132.4, 131.3, 130.0, 129.5, 129.4, 129.1, 128.9, 128.4, 127.9, 126.7, 126.5, 126.0, 125.8, 125.6 (q, *J* = 3.2 Hz), 125.1, 123.9 (q, *J* = 274.5 Hz), 121.2;

¹⁹F NMR (471 MHz, CDCl₃) δ -62.8. (s, 3F);


HRMS (ESI, m/z): calcd. for [M+H]⁺: 390.1100, found: 390.1089.



1g

6-(4-nitrophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1g): yellow solid, m.p. = 189-190 °C, 78.0 mg, 71% yield

¹H NMR (500 MHz, CDCl₃) δ 8.56 – 8.49 (m, 2H), 8.37 – 8.31 (m, 2H), 8.29 – 8.25 (m, 1H), 7.92 (dd, *J* = 9.0, 4.5 Hz, 2H), 7.79 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.56 – 7.51 (m, 3H), 7.50 – 7.45 (m, 1H), 7.39 – 7.31 (m, 2H);
¹³C NMR (126 MHz, CDCl₃) δ 157.3, 154.9, 149.5, 141.3, 137.9, 133.1, 132.5, 131.3, 130.1, 130.0, 129.0, 128.9, 128.4, 128.1, 126.7, 126.5, 126.0, 125.9, 125.3, 123.7, 121.1;
HRMS (ESI, m/z): calcd. for [M+H]⁺: 367.1077, found: 367.1072.




1h

6-(3-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1h): white solid, m.p. = 70-71 °C, 86.3 mg, 81% yield

¹H NMR (500 MHz, CDCl₃) δ 8.36 (d, *J* = 1.9 Hz, 1H), 8.27 (t, *J* = 8.4 Hz, 2H), 7.91 (t, *J* = 7.7 Hz, 2H), 7.81 – 7.76 (m, 1H), 7.55 – 7.43 (m, 6H), 7.37 – 7.32 (m, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 157.5, 155.8, 141.7, 134.7, 134.0, 132.9, 132.3, 131.7, 131.4, 130.0, 129.9, 129.2, 129.1, 128.9, 128.4, 127.8, 127.3, 126.6, 126.4, 126.0, 125.7, 125.1, 121.3;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 356.0837, found: 356.0832.




6-(3-bromophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1i): white solid, m.p. = 60-61 °C, 108.9 mg, 91% yield

¹H NMR (500 MHz, CDCl₃) δ 8.52 (t, *J* = 1.8 Hz, 1H), 8.33 – 8.25 (m, 2H), 7.91 (dd, *J* = 9.2, 6.1 Hz, 2H), 7.78 (dd, *J* = 8.0, 1.7 Hz, 1H), 7.67 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.57 – 7.50 (m, 3H), 7.49 – 7.44 (m, 1H), 7.42 – 7.32 (m, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.5, 155.7, 141.7, 134.6, 134.2, 132.9, 132.4, 132.2, 131.4, 130.1, 130.0, 129.1, 128.9, 128.4, 127.8, 127.7, 126.6, 126.4, 126.0, 125.7, 125.1, 122.8, 121.3;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 400.0332, found: 400.0326.




6-(2-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1j): white solid, m.p. = 50-51 °C, 99.0 mg, 93% yield

¹H NMR (500 MHz, CDCl₃) δ 8.29 (dd, *J* = 6.3, 3.5 Hz, 1H), 7.95 – 7.88 (m, 3H), 7.82 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.56 (d, *J* = 8.7 Hz, 1H), 7.54 – 7.49 (m, 3H), 7.49 – 7.41 (m, 2H), 7.40 – 7.33 (m, 2H), 7.20 (dd, *J* = 8.1, 1.4 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.8, 155.7, 141.5, 133.8, 132.8, 132.4, 132.3, 131.6, 131.5, 131.3, 131.1, 129.9, 128.9, 128.8, 128.4, 127.6, 126.6, 126.5, 126.4, 125.9, 125.7, 125.1, 121.6;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 356.0837, found: 356.0834.




1k

6-(furan-2-yl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1k): white solid, m.p. = 146–147 °C, 64.4 mg, 69% yield

¹H NMR (500 MHz, CDCl₃) δ 8.3 – 8.2 (m, 1H), 7.9 – 7.9 (m, 2H), 7.8 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.7 (s, 1H), 7.6 (d, *J* = 8.7 Hz, 1H), 7.5 – 7.4 (m, 3H), 7.4 – 7.3 (m, 3H), 6.6 (dd, *J* = 3.4, 1.7 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.7, 149.0, 146.7, 146.6, 141.4, 133.0, 132.3, 131.4, 130.0, 129.0, 128.9, 128.4, 127.6, 126.5, 126.4, 126.1, 125.6, 125.2, 121.1, 117.0, 112.2; **HRMS** (ESI, m/z): calcd. for [M+H]⁺: 312.1019, found: 312.1015.




1l

6-(thiophen-2-yl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1l): white solid, m.p. = 100–101 °C, 67.7 mg, 69% yield

¹H NMR (500 MHz, CDCl₃) δ 8.3 – 8.2 (m, 1H), 8.0 (dd, *J* = 3.7, 1.2 Hz, 1H), 7.9 – 7.9 (m, 2H), 7.8 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.6 – 7.5 (m, 2H), 7.5 – 7.5 (m, 2H), 7.5 – 7.4 (m, 1H), 7.4 – 7.3 (m, 2H), 7.2 (dd, *J* = 5.0, 3.7 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.6, 153.4, 141.8, 137.2, 133.0, 132.2, 131.8, 131.6, 131.5, 129.9, 129.1, 128.8, 128.4, 128.1, 127.6, 126.5, 126.4, 126.1, 125.5, 125.1, 121.4; **HRMS** (ESI, m/z): calcd. for [M+Na]⁺: 350.0610, found: 350.0612.




1m

6-(4-chlorophenyl)-2-methylbenzo[f]naphtho[2,1-d][1,3]oxazepane (1m): white solid, m.p. = 130-131 °C, 104.0 mg, 94% yield

¹H NMR (500 MHz, CDCl₃) δ 8.3 (d, *J* = 8.5 Hz, 3H), 7.9 – 7.9 (m, 2H), 7.6 – 7.5 (m, 6H), 7.2 (dd, *J* = 8.3, 2.1 Hz, 1H), 7.2 (d, *J* = 8.3 Hz, 1H), 2.4 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 156.5, 155.5, 141.8, 138.0, 134.6, 133.1, 132.3, 131.4, 130.7, 130.6, 130.5, 128.9, 128.8, 128.7, 128.4, 127.8, 126.5, 126.4, 126.0, 125.5, 120.9, 21.0;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 370.0993, found: 370.0990.




6-(4-chlorophenyl)-2-ethylbenzo[f]naphtho[2,1-d][1,3]oxazepane (1n): white solid, m.p. = 139-140 °C, 102.3 mg, 89% yield

¹H NMR (500 MHz, CDCl₃) δ 8.39 – 8.25 (m, 3H), 7.97 – 7.87 (m, 2H), 7.63 (d, *J* = 2.1 Hz, 1H), 7.58 – 7.49 (m, 5H), 7.29 (d, *J* = 1.8 Hz, 1H), 7.25 (d, *J* = 8.3 Hz, 1H), 2.73 (q, *J* = 7.5 Hz, 2H), 1.29 (t, *J* = 7.5 Hz, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 156.4, 155.6, 141.8, 140.9, 138.0, 132.3, 132.1, 131.4, 130.7, 130.6, 129.4, 128.9, 128.8, 128.7, 128.4, 127.9, 126.5, 126.4, 126.0, 125.5, 120.9, 28.4, 15.8;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 384.1150, found: 384.1147.




6-(4-chlorophenyl)-2-vinylbenzo[f]naphtho[2,1-d][1,3]oxazepane (1o): white solid, m.p. = 50-51 °C, 61.7 mg, 54% yield

¹H NMR (500 MHz, CDCl₃) δ 8.28 (d, *J* = 8.5 Hz, 3H), 7.92 – 7.86 (m, 2H), 7.77 (d, *J* = 2.2 Hz, 1H), 7.54 – 7.42 (m, 6H), 7.24 (d, *J* = 1.3 Hz, 1H), 6.73 (dd, *J* = 17.5 Hz, 11.0 Hz, 1H), 5.70 (d, *J* = 17.5 Hz, 1H), 5.26 (d, *J* = 11.0 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.1, 156.2, 141.9, 138.1, 135.7, 134.6, 132.3, 131.4, 130.7, 130.6, 130.5, 129.2, 129.0, 128.9, 128.4, 127.5, 127.4, 126.7, 126.2, 126.0, 125.6, 121.4, 114.5;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 382.0993, found: 382.0988.




6-(4-chlorophenyl)-2-phenylbenzo[f]naphtho[2,1-d][1,3]oxazepane (1p): white solid, m.p. = 139–140 °C, 109.9 mg, 85% yield

¹H NMR (500 MHz, CDCl₃) δ 8.38 – 8.31 (m, 3H), 8.00 (d, J = 2.1 Hz, 1H), 7.93 (dd, J = 9.0, 5.5 Hz, 2H), 7.66 (dd, J = 8.5, 2.5 Hz, 1H), 7.62 – 7.54 (m, 3H), 7.56 – 7.47 (m, 4H), 7.44 (t, J = 7.8 Hz, 2H), 7.40 – 7.34 (m, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 157.0, 156.3, 142.0, 140.0, 138.2, 132.3, 131.5, 131.4, 130.6, 130.5, 129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 127.7, 127.5, 127.2, 126.8, 126.3, 126.0, 125.7, 121.6;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 432.1150, found: 432.1142.




6-(4-chlorophenyl)-2-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepane (1q): white solid, m.p. = 135–136 °C, 114.3 mg, 99% yield

¹H NMR (500 MHz, CDCl₃) δ 8.38 – 8.34 (m, 1H), 8.29 (d, J = 8.6 Hz, 2H), 7.94 – 7.84 (m, 2H), 7.53 – 7.46 (m, 5H), 7.29 (d, J = 3.1 Hz, 1H), 7.22 (d, J = 8.9 Hz, 1H), 6.98 (dd, J = 8.9, 3.1 Hz, 1H), 3.80 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 156.7, 156.5, 151.3, 142.0, 138.1, 132.3, 131.4, 130.7, 130.6, 129.8, 129.0, 128.9, 128.5, 127.5, 126.6, 126.3, 126.0, 125.6, 121.8, 117.2, 115.6, 55.9;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 386.0942, found: 386.0939.



6-(4-chlorophenyl)-2-(trifluoromethyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1r):


white solid, m.p. = 109-110 °C, 125.8 mg, 99% yield

¹H NMR (500 MHz, CDCl₃) δ 8.32 – 8.23 (m, 1H), 8.15 (d, *J* = 8.1 Hz, 1H), 8.08 – 8.06 (m, 2H), 7.94 (d, *J* = 8.3 Hz, 2H), 7.71 (dd, *J* = 8.5, 2.1 Hz, 1H), 7.60 – 7.46 (m, 5H), 7.42 (d, *J* = 8.5 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 159.5, 155.7, 142.0, 138.5, 132.4, 131.1, 130.6, 130.2, 130.1, 129.9, 129.7, 129.1, 128.7, 127.6 (q, *J* = 33.0 Hz), 127.3, 126.8, 126.2, 126.0, 125.9, 125.5, 123.9 (q, *J* = 272.8 Hz), 122.1;

¹⁹F NMR (471 MHz, CDCl₃) δ -61.9 (s, 3F);

HRMS (ESI, m/z): calcd. for [M+H]⁺:424.0711, found: 424.0705.




1s

6-(4-chlorophenyl)-3-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepane(1s): white solid, m.p. = 209-210 °C, 85.5 mg, 74% yield

¹H NMR (500 MHz, CDCl₃) δ 8.29 (d, *J* = 8.3 Hz, 2H), 8.26 – 8.21 (m, 1H), 7.92 – 7.88 (m, 1H), 7.85 (d, *J* = 8.7 Hz, 1H), 7.67 (d, *J* = 8.7 Hz, 1H), 7.54 – 7.45 (m, 5H), 6.92 (dd, *J* = 8.8, 2.5 Hz, 1H), 6.84 (d, *J* = 2.5 Hz, 1H), 3.86 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 161.3, 158.3, 155.6, 141.2, 138.0, 133.2, 132.3, 131.4, 130.7, 130.5, 128.9, 128.4, 128.2, 127.6, 126.5, 126.4, 126.0, 125.5, 121.4, 111.1, 106.7, 55.7;

HRMS (ESI, m/z): calcd. for [M+H]⁺:386.0942, found: 386.0938.




1t

6-(4-chlorophenyl)-4-methylbenzo[f]naphtho[2,1-d][1,3]oxazepane(1t): white solid, m.p. = 104-105 °C, 80.8 mg, 73% yield

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 8.7 Hz, 3H), 7.93 – 7.85 (m, 2H), 7.57 (d, *J* = 2.1 Hz, 1H), 7.55 – 7.48 (m, 3H), 7.47 (d, *J* = 8.6 Hz, 2H), 7.27 – 7.17 (m, 2H), 2.40 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.4, 157.3, 141.8, 137.5, 132.4, 132.3, 131.6, 131.3, 130.8, 130.6, 130.4, 128.9, 128.7, 128.5, 128.3, 128.2, 126.5, 126.4, 126.0, 125.6, 124.6, 17.6;

HRMS (ESI, m/z): calcd. for [M+H]⁺:370.0993, found: 370.0990.




6-(4-chlorophenyl)-4-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepane (1u): white solid, m.p. = 185–186 °C, 71.6 mg, 62% yield

¹H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 8.54 (s, 1H), 8.30 – 8.22 (m, 1H), 7.92 – 7.85 (m, 2H), 7.52 – 7.47 (m, 3H), 7.45 (d, *J* = 1.9 Hz, 1H), 7.44 (d, *J* = 1.9 Hz, 1H), 7.30 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.24 (t, *J* = 8.0 Hz, 1H), 7.01 (dd, *J* = 8.1, 1.5 Hz, 1H), 3.93 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.7, 151.7, 147.3, 141.9, 137.9, 132.3, 131.6, 131.5, 131.0, 130.4, 128.8, 128.4, 128.3, 128.0, 126.5, 126.4, 126.0, 125.6, 124.9, 124.4, 111.8, 56.0;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 386.0942, found: 386.0940.



6-(4-chlorophenyl)-4-fluorobenzo[f]naphtho[2,1-d][1,3]oxazepane (1v)


: white solid, m.p. = 157–158 °C, 96.2 mg, 86% yield

¹H NMR (500 MHz, CDCl₃) δ 8.42 (d, *J* = 8.7 Hz, 2H), 8.23 (dd, *J* = 6.3, 3.4 Hz, 1H), 7.91 (dd, *J* = 9.0, 2.5 Hz, 2H), 7.55 – 7.49 (m, 4H), 7.47 (d, *J* = 8.7 Hz, 2H), 7.31 – 7.25 (m, 1H), 7.23 (dd, *J* = 10.1, 8.4 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 156.7, 154.4(d, *J* = 248.9 Hz), 145.5(d, *J* = 12.3 Hz), 141.8, 138.4, 132.3, 131.7, 131.4, 131.0 (d, *J* = 3.9 Hz), 130.3, 129.3, 128.8, 128.5, 127.8(d, *J* = 3.5 Hz), 127.1(d, *J* = 2.5 Hz), 126.8, 126.1(d, *J* = 7.4 Hz), 125.8, 125.2 (d, *J* = 7.8 Hz), 116.2, 116.1;

¹⁹F NMR (471 MHz, CDCl₃) δ -130.9 (s, 1F);


HRMS (ESI, m/z): calcd. for [M+H]⁺: 374.0742, found: 374.0737.



4-chloro-6-(4-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane (1w): white solid, m.p. = 160-161 °C, 100.3 mg, 86% yield

¹H NMR (500 MHz, CDCl₃) δ 8.49 – 8.42 (m, 2H), 8.19 – 8.09 (m, 1H), 7.94 – 7.82 (m, 2H), 7.61 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.55 – 7.41 (m, 6H), 7.23 (t, *J* = 7.9 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.0, 153.9, 141.7, 138.1, 132.4, 131.5, 131.4, 131.3, 130.9, 130.8, 130.1, 129.3, 128.5, 128.4, 127.1, 126.7, 126.5, 126.0, 125.9, 125.8, 125.3; **HRMS** (ESI, m/z): calcd. for [M+H]⁺: 390.0447, found: 390.0441.




6-(4-chlorophenyl)dinaphtho[2,1-d:2',1'-f][1,3]oxazepane(1x): white solid, m.p. = 185-186 °C, 99.6 mg, 82% yield

¹H NMR (500 MHz, CDCl₃) δ 8.51 – 8.46 (m, 1H), 8.31 – 8.25 (m, 2H), 8.23 – 8.18 (m, 1H), 7.95 – 7.88 (m, 3H), 7.80 (q, *J* = 8.6 Hz, 2H), 7.59 – 7.55 (m, 3H), 7.53 – 7.49 (m, 2H), 7.47 (d, *J* = 8.6 Hz, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 157.1, 153.1, 142.0, 137.6, 134.6, 132.3, 131.8, 131.4, 130.4, 129.4, 129.0, 128.6, 128.5, 127.9, 127.8, 127.5, 126.9, 126.7, 126.6, 126.5, 125.9, 125.8, 124.5, 124.5, 122.0;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 406.0993, found: 406.0987.




15-(4-chlorophenyl)benzo[2,3]benzofuro[5,4-f]naphtho[2,1-d][1,3]oxazepane(1y): white solid, m.p. = 190-191 °C, 130.8 mg, 98% yield

¹H NMR (500 MHz, CDCl₃) δ 8.34 (d, *J* = 7.8 Hz, 1H), 8.19 (d, *J* = 8.2 Hz, 2H), 8.10 (d, *J* = 8.1 Hz, 1H), 7.90 (dd, *J* = 8.3, 4.6 Hz, 2H), 7.76 (d, *J* = 8.6 Hz, 1H), 7.63 (d, *J* = 8.3 Hz, 1H), 7.56 – 7.50 (m, 5H), 7.43 – 7.36 (m, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.7, 157.1, 156.2, 154.7, 141.2, 137.6, 132.5, 132.0, 131.8, 131.5, 130.8, 128.7, 128.6, 128.5, 128.4, 128.0, 127.5, 126.6, 126.3, 125.7, 123.6, 123.0, 122.5, 122.2, 117.1, 111.9, 108.4;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 446.0942, found: 446.0943.




6-(4-chlorophenyl)-12-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepane(1z): white solid, m.p. = 139-140 °C, 114.3 mg, 99% yield

¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, *J* = 8.3 Hz, 2H), 7.86 (d, *J* = 7.9 Hz, 1H), 7.81 (dd, *J* = 8.8, 3.7 Hz, 2H), 7.66 (s, 1H), 7.52 – 7.37 (m, 4H), 7.36 – 7.28 (m, 2H), 7.21 – 7.15 (m, 1H), 3.85 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 158.4, 157.4, 156.2, 142.4, 138.1, 132.7, 132.2, 130.7, 130.6, 129.9, 129.8, 129.5, 128.9, 128.6, 127.6, 126.5, 125.0, 123.7, 121.4, 117.6, 105.7, 55.3;

HRMS (ESI, m/z): calcd. for [M+H]⁺:386.0942, found: 386.0937.




12-(benzyloxy)-6-(4-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane(1aa):

white solid, m.p. = 142-143 °C, 128.6 mg, 93% yield

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 8.3 Hz, 2H), 7.82 (dd, *J* = 8.8, 4.7 Hz, 2H), 7.66 (d, *J* = 2.3 Hz, 1H), 7.60 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.48 (d, *J* = 8.5 Hz, 2H), 7.47 – 7.37 (m, 6H), 7.36 (d, *J* = 7.0 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 1H), 7.30 – 7.24 (m, 1H), 7.21 (t, *J* = 7.5 Hz, 1H), 5.15 (d, *J* = 12.0 Hz, 1H), 5.12 (d, *J* = 12.0 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.4, 157.3, 156.2, 142.4, 138.1, 136.9, 132.5, 132.2, 130.7, 130.6, 130.0, 129.7, 129.4, 128.9, 128.7, 128.6, 128.0, 127.7, 127.4, 126.5, 125.1, 123.8, 121.3, 118.2, 107.1, 69.8;


HRMS (ESI, m/z): calcd. for [M+H]⁺:462.1255, found: 462.1248.



11-bromo-6-(4-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepane(1ab): white solid, m.p. = 205-206 °C, 55.7 mg, 43% yield

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 8.6 Hz, 2H), 8.12 (d, *J* = 9.1 Hz, 1H), 8.05 (d, *J* = 2.1 Hz, 1H), 7.79 (d, *J* = 8.7 Hz, 1H), 7.70 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.59 – 7.51 (m, 2H), 7.50 – 7.44 (m, 3H), 7.37 – 7.30 (m, 2H);

¹³C NMR (126 MHz, CDCl₃) δ 157.5, 156.5, 142.0, 138.3, 133.4, 132.7, 130.6, 130.5, 130.3, 130.2, 129.9, 129.7, 128.9, 128.7, 128.2, 128.0, 127.7, 127.2, 125.2, 121.4, 119.7; **HRMS** (ESI, m/z): calcd. for [M+H]⁺:433.9942, found: 433.9935.




6-(4-chlorophenyl)-11-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepane(1ac): white solid, m.p. = 172-173 °C, 92.4 mg, 80% yield

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, *J* = 8.3 Hz, 2H), 8.17 (d, *J* = 9.3 Hz, 1H), 7.78 (d, *J* = 8.7 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.54 – 7.40 (m, 4H), 7.35 – 7.28 (m, 2H), 7.21 (d, *J* = 2.7 Hz, 1H), 7.17 (dd, *J* = 9.3, 2.6 Hz, 1H), 3.96 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.4, 157.3, 155.6, 140.0, 137.9, 133.7, 132.9, 130.8, 130.4, 129.9, 129.3, 128.9, 128.1, 128.0, 127.7, 126.6, 126.5, 125.0, 121.3, 118.9, 106.6, 55.4;

HRMS (ESI, m/z): calcd. for [M+H]⁺:386.0942, found: 386.0938.




6-(4-chlorophenyl)-11-phenylbenzo[f]naphtho[2,1-d][1,3]oxazepane(1ad): white solid, m.p. = 139-140 °C, 64.7 mg, 50% yield

¹H NMR (500 MHz, CDCl₃) δ 8.33 (t, *J* = 8.7 Hz, 3H), 8.11 (s, 1H), 7.94 (d, *J* = 8.7 Hz, 1H), 7.84 – 7.72 (m, 4H), 7.59 – 7.44 (m, 6H), 7.44 – 7.31 (m, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.5, 156.2, 141.8, 140.6, 138.2, 138.1, 132.9, 132.6, 130.7, 130.6, 130.5, 130.0, 129.2, 129.1, 129.0, 128.9, 127.7, 127.6, 127.3, 127.0, 126.5, 126.2, 126.1, 125.1, 121.3;

HRMS (ESI, m/z): calcd. for [M+Na]⁺:454.0969, found: 454.0966.




1ae

6-(4-chlorophenyl)anthra[2,1-d]benzo[f][1,3]oxazepane(1ae): white solid, m.p. = 140-141 °C, 96.0 mg, 79% yield

¹H NMR (500 MHz, CDCl₃) δ 8.83 (s, 1H), 8.47 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 2H), 8.04 (dd, *J* = 8.6, 3.3 Hz, 2H), 7.94 (d, *J* = 7.9 Hz, 2H), 7.52 – 7.45 (m, 6H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.36 (d, *J* = 8.1 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.2, 156.0, 141.3, 138.1, 132.8, 132.0, 131.2, 130.7, 130.6, 130.5, 130.1, 129.7, 129.5, 129.2, 128.9, 128.5, 127.9, 127.1, 126.6, 126.2, 125.8, 125.7, 125.5, 125.2, 121.4;

HRMS (ESI, m/z): calcd. for [M+H]⁺:406.0993, found: 406.0987.




1af

11-methyl-6-(4-nitrophenyl)dibenzo[d,f][1,3]oxazepane(1af): yellow solid, m.p. = 210-211 °C, 82.17 mg, 83% yield

¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, *J* = 8.5 Hz, 2H), 8.34 (d, *J* = 8.6 Hz, 2H), 7.56 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.43 – 7.33 (m, 2H), 7.31 – 7.26 (m, 4H), 2.55 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 157.1, 154.9, 149.5, 144.1, 138.1, 136.5, 132.0, 131.2, 129.9, 129.6, 129.5, 129.3, 128.0, 125.0, 124.9, 123.7, 120.6, 22.1;

HRMS (ESI, m/z): calcd. for [M+Na]⁺:353.0897, found: 353.0901.




1ag

11-chloro-6-(4-nitrophenyl)dibenzo[d,f][1,3]oxazepane (1ag): white solid, m.p. = 198-199 °C, 88.2 mg, 84% yield

¹H NMR (500 MHz, CDCl₃) δ 8.50 (s, 1H), 8.48 (s, 1H), 8.35 (d, *J* = 8.5 Hz, 2H), 7.98 (d, *J* = 7.8 Hz, 1H), 7.49 – 7.41 (m, 2H), 7.38 (t, 2H), 7.33 (t, *J* = 7.7 Hz, 1H), 7.28 (d, *J* = 3.4 Hz, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 156.9, 156.1, 149.8, 145.3, 137.6, 132.7, 132.3, 130.2, 130.1, 130.0, 128.8, 128.7, 127.5, 126.0, 125.0, 123.8, 120.5;

HRMS (ESI, m/z): calcd. for [M+Na]⁺: 373.0350, found: 373.0354.




1ah

6-(4-chlorophenyl)benzo[d]naphtho[1,2-f][1,3]oxazepane (1ah): white solid, m.p. = 50-52°C, 96.0mg, 90% yield

¹H NMR (500 MHz, CDCl₃) δ 8.29 – 8.21 (m, 3H), 7.88 – 7.78 (m, 3H), 7.56 – 7.43 (m, 6H), 7.39 (d, *J* = 8.9 Hz, 1H), 7.37 – 7.31 (m, 1H);

¹³C NMR (126 MHz, CDCl₃) δ 157.1, 156.0, 145.5, 138.1, 132.4, 131.9, 131.8, 130.7, 130.4, 130.1, 129.8, 128.9, 128.4, 128.3, 127.1, 126.7, 126.1, 125.8, 125.5, 124.7, 120.0;

HRMS (ESI, m/z): calcd. for [M+H]⁺: 356.0837, found: 356.0836.




(rac)-1ai

6-(4-chlorophenyl)-1,3-dimethylbenzo[f]naphtho[2,1-d][1,3]oxazepane(1ai): white solid, m.p. = 140-141 °C, 68.9 mg, 60% yield; For kinetic resolution, 49% yield, 96:4 er

¹H NMR (500 MHz, CDCl₃) δ 8.29 (d, *J* = 8.2 Hz, 2H), 7.93 – 7.84 (m, 2H), 7.68 – 7.62 (m, 1H), 7.53 (d, *J* = 8.7 Hz, 1H), 7.47 (dd, *J* = 8.9, 5.0 Hz, 4H), 7.01 (s, 1H), 6.96 (s, 1H), 2.38 (s, 3H), 2.00 (s, 3H);

¹³C NMR (126 MHz, CDCl₃) δ 159.9, 157.8, 143.0, 139.4, 139.3, 138.0, 131.4, 131.3, 130.8, 130.4, 129.1, 128.9, 128.4, 128.3, 127.3, 127.1, 126.3, 125.4, 125.3, 125.0, 118.6, 21.9, 21.1;


HRMS (ESI, m/z): calcd. for [M+H]⁺: 384.1150, found: 384.1140.




(S)-1ai

HPLC analysis: 96:4 er, (CHIRALCEL IA column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, λ = 254 nm, $t_{\text{major}}=4.1$ min, $t_{\text{minor}}=7.7$ min), $[\alpha]_D^{25}=+136.00$ ($c=0.2$, acetone).


X-ray structure of 1c and 2c




1c



Deposition No. CCDC 2256876





2c









Deposition No. CCDC 2256877



¹H, ¹³C, ¹⁹F and HPLC charts









































































































































149.522
145.181
143.214
143.145
141.210
135.725
134.330
130.231
129.394
124.667
122.450























< 157.686
< 157.506



142.403
142.185
132.785
132.785
132.143
131.450
129.744
129.382
129.351
129.328
128.727
128.382
127.569
126.455
126.381
126.142
125.405
124.812
121.445

-21.691















8.525
8.521
8.518
8.315
8.299
8.296
8.294
8.285
8.279
8.275
8.266
7.925
7.792
7.788
7.912
7.906
7.895
7.792
7.776
7.773
7.677
7.674
7.671
7.662
7.659
7.656
7.555
7.538
7.525
7.520
7.517
7.513
7.511
7.506
7.466
7.462
7.450
7.447
7.400
7.385
7.369
7.358
7.356
7.349
7.346
7.342
7.333
7.329
7.326











1k










11











11















































































1ae





1ae

















Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.007	31084559	982380	49.884	53.599
2	21.387	31228712	850445	50.116	46.401
Total		62313271	1832825	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	15.627	1813245	55048	4.492	4.546
2	18.240	38556974	1155838	95.508	95.454
Total		40370219	1210886	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.007	31084559	982380	49.884	53.590
2	21.387	31228712	850445	50.116	46.410
Total		62313271	1832825	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.267	511485	15888	2.184	2.635
2	22.920	22908346	586916	97.816	97.365
Total		23419831	602804	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	21.260	27780700	741451	49.719	52.596
2	25.660	28094760	668244	50.281	47.404
Total		55875460	1409695	100.000	100.000





Peaks#	Ret.Time	Area	Height	Area%	Height%
1	22.467	423384	11730	1.275	1.502
2	26.740	32795642	768765	98.725	98.498
Total		33219026	780495	100.000	100.000






Peaks#	Ret.Time	Area	Height	Area%	Height%
1	20.249	5013065	131958	49.628	52.765
2	23.702	5088189	118128	50.372	47.235
Total		10101254	250085	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	21.600	790488	20179	1.778	1.914
2	24.940	43660712	1033816	98.222	98.086
Total		44451200	1053995	100.000	100.000









Peaks#	Ret.Time	Area	Height	Area%	Height%
1	32.580	4107591	71029	49.431	51.645
2	34.927	4202085	66502	50.569	48.355
Total		8309676	137531	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	33.160	537638	10912	1.054	1.338
2	35.560	50456422	804848	98.946	98.662
Total		50994060	815760	100.000	100.00




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	15.627	20694581	699614	49.629	52.868
2	18.773	21003568	623684	50.371	47.132
Total		41698149	1323298	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	15.953	873812	28971	2.846	3.148
2	18.927	29824442	891210	97.154	96.852
Total		30698254	920181	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.440	12697534	394779	50.017	53.222
2	20.980	12689077	346977	49.983	46.778
Total		25386611	741756	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.320	769853	25210	2.471	3.008
2	20.600	29054737	812820	97.529	96.992
Total		29824590	838030	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	23.713	8526928	212990	49.628	51.978
2	26.560	8654689	196777	50.372	48.022
Total		17181617	409767	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	23.273	49154995	1206029	96.845	97.050
2	26.480	1601158	36650	3.155	2.950
Total		50756153	1242679	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.327	15288670	415792	48.480	52.812
2	22.480	16247479	371504	51.520	47.188
Total		31536149	787296	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.433	1253985	36954	4.010	5.052
2	22.273	30017377	731435	95.990	94.948
Total		31271362	768389	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.260	12089392	343635	49.385	53.155
2	20.947	12390425	302834	50.615	46.845
Total		50075777	646469	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.113	724051	19841	2.676	3.069
2	21.580	26328312	626484	97.324	96.931
Total		27052363	646325	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.187	22752535	712578	49.190	53.585
2	23.233	23501585	617217	50.810	46.415
Total		46254120	1329795	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	17.407	34357580	1045314	96.649	96.936
2	22.553	1191291	33040	3.351	3.064
Total		35548871	1078354	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	19.433	15114291	479369	49.930	54.396
2	23.733	15156624	401885	50.070	45.604
Total		30270915	881254	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	18.240	48449561	1519122	94.606	95.427
2	22.513	2762270	72800	5.394	4.573
Total		51211831	1591922	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	21.360	65428495	1758031	49.301	55.694
2	26.593	67282841	1398559	50.699	44.306
Total		132711336	3156590	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	21.353	1837339	49202	7.072	8.465
2	26.527	24143490	532016	92.928	91.535
Total		25980829	581218	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	27.180	34341985	649538	50.171	52.135
2	33.447	34107845	596347	49.829	47.865
Total		68449830	1245885	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.587	62347233	1125676	93.447	93.029
2	33.447	4371768	84350	6.553	6.971
Total		66719001	1210026	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.100	23528097	519203	49.790	53.029
2	30.088	23726774	459898	50.210	46.971
Total		47254871	979100	100.000	100.000



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.160	11246452	242733	95.571	95.995
2	30.333	521173	10127	4.429	4.005
Total		11767625	252860	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	11.876	9910933	323520	50.634	55.382
2	13.587	9662698	260643	49.366	44.618
Total		19573632	584163	100.000	100.000





Peaks#	Ret.Time	Area	Height	Area%	Height%
1	11.851	15724735	497987	97.960	97.965
2	13.881	327488	10346	2.040	2.035
Total		16052223	508333	100.000	100.000

mV




mV







Peaks#	Ret.Time	Area	Height	Area%	Height%
1	9.213	2552141	93458	50.719	81.683
2	16.280	2479825	20957	49.281	18.317
Total		5031966	114415	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	9.273	635181	30747	3.466	14.610
2	15.400	17688270	179699	96.534	85.390
Total		18323451	210446	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	32.180	15020628	273750	48.578	62.419
2	55.187	15900162	164818	51.422	37.581
Total		30920790	438568	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	30.593	807374	15099	1.100	1.778
2	51.913	72598630	833846	98.900	98.222
Total		73406004	848945	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.080	16491719	306278	49.628	53.812
2	28.802	16739195	262886	50.372	46.188
Total		33230914	569164	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.368	298092	6721	0.729	1.070
2	28.357	40574314	621444	99.271	98.930
Total		40872406	628166	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	23.456	9799308	142811	50.198	54.706
2	28.686	9722037	118242	49.802	45.294
Total		19521345	261053	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	23.621	662488	11214	2.533	3.253
2	27.903	25495647	333500	97.467	96.747
Total		26158136	344714	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	26.827	53048064	1239727	50.046	51.238
2	27.973	52950676	1179796	49.954	48.762
Total		105998740	2419523	100.000	100.000



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	27.293	51399147	1175905	95.899	95.405
2	29.067	2197879	56630	4.101	4.595
Total		53597026	1232535	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.397	26242106	449287	50.203	58.788
2	26.891	26029898	314962	49.797	41.212
Total		52272004	764248	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.868	3996950	68610	7.194	9.827
2	26.542	51562499	629570	92.806	90.173
Total		55559449	698181	100.000	100.000

mV




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	10.836	21867318	781224	50.052	52.882
2	12.185	21821687	696072	49.948	47.118
Total		43689004	1477296	100.000	100.000


mV



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	10.768	32822001	1089745	96.200	95.986
2	12.325	1296599	45577	3.800	4.014
Total		34118600	1135323	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	19.436	10531239	285393	49.759	55.046
2	24.623	10633273	233068	50.241	44.954
Total		21164512	518461	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	19.560	1371065	36280	3.006	4.223
2	25.175	44246060	822829	96.994	95.777
Total		45617126	859110	100.000	100.000


mV




mV




mV




mV




mV




mV







Peaks#	Ret.Time	Area	Height	Area%	Height%
1	19.731	1640871	41659	49.973	53.179
2	22.372	1642656	36679	50.027	46.821
Total		3283526	78338	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	19.490	1679220	42532	1.974	2.142
2	21.997	83403066	1943122	98.026	97.858
Total		85082286	1985654	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	15.952	6684644	201369	50.363	54.994
2	21.140	6588161	164795	49.637	45.006
Total		13272805	366164	100.000	100.000



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.336	13923168	413052	94.013	94.833
2	22.044	886733	22503	5.987	5.167
Total		14809901	435555	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.378	21430737	582885	50.541	55.135
2	22.194	20972063	474306	49.459	44.865
Total		42402799	1057191	100.000	100.000





Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.373	16257081	415207	94.975	95.426
2	22.462	860139	19900	5.025	4.574
Total		17117220	435106	100.000	100.000

mV




mV








Peaks#	Ret.Time	Area	Height	Area%	Height%
1	14.687	21919152	877224	50.254	54.244
2	18.073	21697571	739931	49.746	45.756
Total		43616723	1617155	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	14.674	6792476	261912	48.822	52.730
2	17.702	7120224	234793	51.178	47.270
Total		13912699	496706	100.000	100.000

Kinetic resolution of racemic biaryl oxazepane **1ai**







Peaks#	Ret.Time	Area	Height	Area%	Height%
1	14.687	21919152	877224	50.254	54.244
2	18.073	21697571	739931	49.746	45.756
Total		43616723	1617155	100.000	100.000





Peaks#	Ret.Time	Area	Height	Area%	Height%
1	15.026	366616	15751	5.404	6.742
2	18.082	6418073	217877	94.596	93.258
Total		6784689	233628	100.000	100.000



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	22.272	7538779	241850	50.000	74.550
2	57.521	7538703	82561	50.000	25.450
Total		15077482	324411	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	22.253	18898468	601464	98.121	99.291
2	58.542	361975	4293	1.879	0.709
Total		19260443	605756	100.000	100.000




Peaks#	Ret.Time	Area	Height	Area%	Height%
1	24.521	25065324	388505	99.628	99.983
2	26.738	93662	65	0.372	0.017
Total		25158986	388570	100.000	100.000

mV



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.341	3643237	154066	50.395	60.160
2	23.643	3586055	102029	49.605	39.840
Total		7229292	256095	100.000	100.000

mV



Peaks#	Ret.Time	Area	Height	Area%	Height%
1	16.376	1455369	61489	95.241	95.942
2	23.731	72729	2601	4.759	4.058
Total		1528098	64090	100.000	100.000

References

- [1] Liang, Y.; Ji, J.; Zhang, X.; Jiang, Q.; Luo, J.; Zhao, X. Enantioselective construction of axially chiral amino sulfide vinyl arenes by chiral sulfide-catalyzed electrophilic carbothiolation of alkynes. *Angew. Chem., Int. Ed.* **2020**, *59*, 4959-4964.
- [2] Cho, J. Y.; Roh, G.-b.; Cho, E. J. Visible-light-promoted synthesis of dibenzofuran derivatives. *J. Org. Chem.* **2018**, *83*, 805-811.
- [3] Wang, M.; Liu, Y.; Wang, L.; Lu, H.; Feng, L.; Gao, H. Cascade chan-lam c-o coupling/[3,3]-rearrangement of arylhydroxylamines with arylboronic acids toward nobin analogues. *Adv. Synth. Catal.* **2021**, *363*, 1733-1738.
- [4] Yang, Y.; Zhu, S.-F.; Duan, H.-F.; Zhou, C.-Y.; Wang, L.-X.; Zhou, Q.-L. Asymmetric Reductive Coupling of Dienes and Aldehydes Catalyzed by Nickel Complexes of Spiro Phosphoramidites: Highly Enantioselective Synthesis of Chiral Bishomoallylic Alcohols. *J. Am. Chem. Soc.* **2007**, *129*, 2248-2249.
- [5] a) Ahmed, A.; Bragg, R. A.; Clayden, J.; Lai, L. W.; McCarthy, C.; Pink, J. H.; Westlund, N.; Yasin, S. A., Barriers to rotation about the chiral axis of tertiary aromatic amides. *Tetrahedron* **1998**, *54*, 13277-13294; b) Curran, D. P.; Liu, W.; Chen, C. H.-T., Transfer of Chirality in Radical Cyclizations. Cyclization of o-Haloacrylanilides to Oxindoles with Transfer of Axial Chirality to a Newly Formed Stereocenter. *J. Am. Chem. Soc.* **1999**, *121*, 11012-11013.

Full reference for Gaussian software:

Gaussian 16, Revision B.01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford CT, 2016.

- [6] Bannwarth, C.; Ehlert, S.; Grimme, S. GFN2-XTB - An Accurate and Broadly Parametrized Self-Consistent Tight-Binding Quantum Chemical Method with

- Multipole Electrostatics and Density-Dependent Dispersion Contributions. *J. Chem. Theory Comput.* **2019**, *15* (3), 1652–1671.
- [7] Grimme, S.; Bannwarth, C.; Shushkov, P. A Robust and Accurate Tight-Binding Quantum Chemical Method for Structures, Vibrational Frequencies, and Noncovalent Interactions of Large Molecular Systems Parametrized for All Spd-Block Elements ($Z = 1\text{--}86$). *J. Chem. Theory Comput.* **2017**, *13* (5), 1989–2009.
- [8] Bannwarth, C.; Caldeweyher, E.; Ehlert, S.; Hansen, A.; Pracht, P.; Seibert, J.; Spicher, S.; Grimme, S. Extended Tight-Binding Quantum Chemistry Methods. *Wiley Interdiscip. Rev. Comput. Mol. Sci.* **2021**, *11* (2).
- [9] Grimme, S. Exploration of Chemical Compound, Conformer, and Reaction Space with Meta-Dynamics Simulations Based on Tight-Binding Quantum Chemical Calculations. *J. Chem. Theory Comput.* **2019**, *15* (5), 2847–2862.
- [10] Pracht, P.; Bohle, F.; Grimme, S. Automated Exploration of the Low-Energy Chemical Space with Fast Quantum Chemical Methods. *Phys. Chem. Chem. Phys.* **2020**, *22* (14), 7169–7192.
- [11] Frisch, M. J. .; Trucks, G. W. .; Schlegel, H. B. .; Scuseria, G. E. .; Robb, M. A. .; Cheeseman, J. R. .; Scalmani, G. .; Barone, V. .; Petersson, G. A. .; Nakatsuji, H. .; et al. Gaussian 16, Revision B.01. 2016.
- [12] Zhao, Y.; Truhlar, D. G. The M06 Suite of Density Functionals for Main Group Thermochemistry, Thermochemical Kinetics, Noncovalent Interactions, Excited States, and Transition Elements: Two New Functionals and Systematic Testing of Four M06-Class Functionals and 12 Other Function. *Theor. Chem. Acc.* **2008**, *120* (1), 215–241.
- [13] Weigend, F.; Ahlrichs, R. Balanced Basis Sets of Split Valence, Triple Zeta Valence and Quadruple Zeta Valence Quality for H to Rn: Design and Assessment of Accuracy. *Phys. Chem. Chem. Phys.* **2005**, *7* (18), 3297–3305.
- [14] Weigend, F. Accurate Coulomb-Fitting Basis Sets for H to Rn. *Phys. Chem. Chem. Phys.* **2006**, *8* (9), 1057–1065.
- [15] Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Universal Solvation Model

Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. *J. Phys. Chem. B* **2009**, *113* (18), 6378–6396.

- [16] Luchini, G.; Alegre-Requena, J. V.; Funes-Ardoiz, I.; Paton, R. S.; Pollice, R. GoodVibes: Automated Thermochemistry for Heterogeneous Computational Chemistry Data. **2020**, *9*, 291.
- [17] Contreras-García, J.; Johnson, E. R.; Keinan, S.; Chaudret, R.; Piquemal, J. P.; Beratan, D. N.; Yang, W. NCIPILOT: A Program for Plotting Noncovalent Interaction Regions. *J. Chem. Theory Comput.* **2011**, *7* (3), 625–632.
- [18] Schrödinger, L. *The PyMOL Molecular Graphics Development Component, Version 1.8*; 2015.
- [19] Fukui, K. The Path of Chemical Reactions - The IRC Approach. *Acc. Chem. Res.* **1981**, *14* (12), 363–368.
- [20] Fukui, K. Formulation of the Reaction Coordinate. *J. Phys. Chem.* **2005**, *74* (23), 4161–4163.
- [21] Yang, X.; Wei, L.; Wu, Y.; Zhou, L.; Zhang, X.; Chi, Y. R. Atroposelective Access to 1,3-Oxazepine-Containing Bridged Biaryls via Carbene-Catalyzed Desymmetrization of Imines. *Angew. Chem. Int. Ed.* **2022**, *62* (1), e202211977.